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Abstract
This review is an effort to summarize recent developments in synthesis of O-glyco-
sides and N-, C-glycosyl molecules with promising antidiabetic potential. Articles 
published after 2000 are included. First, the O-glycosides used in the treatment of 
diabetes are presented, followed by the N-glycosides and finally the C-glycosides 
constituting the largest group of antidiabetic drugs are described. Within each group 
of glycosides, we presented how the structure of compounds representing poten-
tial drugs changes and when discussing chemical compounds of a similar structure, 
achievements are presented in the chronological order. C-Glycosyl compounds mim-
icking O-glycosides structure, exhibit the best features in terms of pharmacody-
namics and pharmacokinetics. Therefore, the largest part of the article is concerned 
with the description of the synthesis and biological studies of various C-glycosides. 
Also N-glycosides such as N-(β-d-glucopyranosyl)-amides, N-(β-d-glucopyranosyl)-
ureas, and 1,2,3-triazolyl derivatives belong to the most potent classes of antidia-
betic agents. In order to indicate which of the compounds presented in the given sec-
tions have the best inhibitory properties, a list of the best inhibitors is presented at 
the end of each section. In summary, the best inhibitors were selected from each of 
the summarizing figures and the results of the ranking were placed. In this way, the 
reader can learn about the structure of the compounds having the best antidiabetic 
activity. The compounds, whose synthesis was described in the article but did not 
appear on the figures presenting the structures of the most active inhibitors, did not 
show proper activity as inhibitors. Thus, the article also presents studies that have 
not yielded the desired results and show directions of research that should not be 
followed. In order to show the directions of the latest research, articles from 2018 to 
2019 are described in a separate Sect. 5. In Sect. 6, biological mechanisms of action 
of the glycosides and patents of marketed drugs are described.
Keywords O-Glycosides · N-Glycosides · C-Glycosides · Diabetes type 2 · Glycogen 
phosphorylase inhibitor · Sodium-dependent glucose cotransporter inhibitor
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Asn  Asparagine
Asp  Aspartic acid
Bn  Benzyl
Boc  tert-Butyloxycarbonyl
iBu  Isobutyl
n-Bu  n-Butyl
t-Bu  tert-Butyl
Bz  Benzoyl
CAN  Cerium ammonium nitrate
CuAAC  Copper-catalyzed azide–alkyne cycloaddition
DBU  1,8-Diazabicyclo[5.4.0]undec-7-ene
DCC  N,N’-Dicyclohexylcarbodiimide
DCM  Dichloromethane
DIAD  Diisopropyl azodicarboxylate
DMAP  N,N-Dimethyl-4-aminopyridine
DME  Dimethoxyethane
DMF  Dimethylformamide
DMSO  Dimethyl sulfoxide
EDCI  N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide
Et  Ethyl
GP  Glycogen phosphorylase
GS  Glycogen synthase
Hetaryl  Heteroaromatic ring
HMPA  Hexamethylphosphoramide
HOBt  Hydroxybenzotriazole
HPLC  High-performance liquid chromatography
IC50  Half maximal inhibitory concentration
Ki  Inhibition constant
LDA  Lithium diisopropylamide
Me  Methyl
MOM  Methoxymethyl
MOMCl  Methoxymethyl chloride
Ms  Mesyl
NBS  N-bromosuccinimide
NCS  N-chlorosuccinimide
NMM  N-Methylmorpholine
NMO  N-Methylmorpholine N-oxide
Ph  Phenyl
iPr  Isopropyl
PTP1B  Protein tyrosine phosphatase 1B
QSAR  Quantitative structure–activity relationship
RMGP  Rat muscle glycogen phosphorylase
SAR  Structure–activity relationship
SGLT  Sodium-dependent glucose cotransporter
TBA  tert-Butyl alcohol
TBAF  Tetrabutylammonium fluoride
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TBDMS  tert-Butyldimethylsilyl
TBDMSCl  tert-Butyldimethylsilyl chloride
TBS  tert-Butyldimethylsilyl
TBSCl  tert-Butyldimethylsilyl chloride
T2DM  Type 2 diabetes mellitus
TEA  Triethylamine
TFA  Trifluoroacetic acid
THF  Tetrahydrofuran
TIPS  Triisopropylsilyl
TMS  Trimethylsilyl
TMSI  Trimethylsilyl iodide
TMSOTf  Trimethylsilyl trifluoromethanesulfonate
Ts  Tosyl
Tyr  Tyrosine
1 Introduction
Diabetes mellitus is a disease closely associated with the metabolic syndrome and in 
developed countries it is a major public health problem [1–3]. There are three main 
types of diabetes mellitus: type 1 (insulin-dependent), type 2 (insulin resistance), 
and gestational diabetes. Type 2 diabetes mellitus (T2DM) accounts for 90–95% of 
the diabetic cases. In T2DM, insulin resistance is the major problem. Chronic hyper-
glycemia is associated with long-term damage, dysfunction and failure of various 
organs such as eyes, kidneys, nerves, heart and blood vessels. While type 1 diabetics 
can be treated by the administration of exogenous insulin, for type 2 patients gen-
erally diet, exercise, and oral hypoglycemic agents are prescribed. A large number 
of oral antidiabetic drugs aimed to eliminate three major metabolic disorders lead-
ing to hyperglycemia-dysfunction of β-cells, peripheral insulin resistance, excessive 
hepatic glucose production [4, 5]. Current pharmacological treatments are sympto-
matic and aim at maintaining the blood glucose levels close to the fasting normo-
glycemic range of 3.5–6 mM/l. This can be achieved by an array of small molecule 
drugs (e.g., biguanides, sulfonylureas, thiazolidinediones, glycosidase inhibitors) 
and ultimately by administration of insulin.
Metformin is a biguanide, which is now the most widely prescribed antidia-
betic drug (Fig.  1). Metformin is the first-line medication for the treatment of 
type 2 diabetes particularly in people who are overweight and is believed to be 
Fig. 1  Metformin—the most 
widely prescribed antidiabetic 
drug
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the most widely used medication for diabetes, which is taken by mouth. However, 
for 30–40% of T2DM patients, combination therapy is frequently applied as phar-
macological treatments.
Glycogen is a polymer of α-1,4- and α-1,6-linked glucose units that provides 
a readily available source of energy in living organisms. Glycogen synthase (GS) 
and glycogen phosphorylase (GP) are the two enzymes that control the synthe-
sis and degradation of this polysaccharide. A key role in glycogen metabolism 
plays GP [6, 7]. With the rapid increase of type 2 diabetic patients recently, it is 
becoming an interesting field to discover GP inhibitors for potential antidiabetic 
drugs. As GP is a typical allosteric protein with several key inhibitor-binding 
sites including the inhibitor, the catalytic, the allosteric, and the new allosteric 
sites, the research works were mainly focused on compounds that can bind these 
sites and show selective inhibitory effect [6–10]. So, GP transfers a glucose unit 
from the non-reducing end of the storage polysaccharide glycogen to an inorganic 
phosphate. Three isoforms of GP exist in the brain, muscle, and liver tissue. The 
liver is capable of storing glucose as glycogen and producing and releasing glu-
cose to the bloodstream [6, 7]. GP is an allosteric enzyme, which exists in two 
interconvertible forms GPa (phosphorylated, active, high substrate affinity) and 
GPb (unphosphorylated, inactive, low substrate affinity). Design of GP inhibi-
tors is a target for a better control of hyperglycemia. The inhibitors targeting the 
seven binding sites of GP show a large molecular diversity. Among them, vari-
ous glucose derivatives bind mostly to the catalytic site of the enzyme. N-Acyl-
β-d-glucopyranosylamines, N-acyl-N′-β-d-glucopyranosyl ureas, glucopyra-
nosylidene-spiro-heterocycles, as well as N- and C-glucosylated heterocycles 
belong to the most potent classes of this inhibitor family [6, 7]. In 2001, So and 
Karplus designed a number of potential GP inhibitors with a variety of computa-
tional approaches [11]. 2D and 3D similarity-based QSAR models were used to 
identify novel molecules that may bind to the glucose-binding site. The designed 
ligands were evaluated by a multiple screening method [12]. In this way, a total of 
301 candidate ligands for GP have been designed using an array of computational 
approaches.
Several kinds of mimics of O-glycosides, first of all S-, N-, and C-glycosyl deriv-
atives, may display similar biological activities; however, due to their significantly 
distinct chemical properties, such molecules can be valuable tools in deciphering the 
biological roles of natural sugars, and may also serve as leads for new drugs. Among 
glycomimetics, C-glycosides have attracted much attention due to the existence of 
a number of naturally occurring representatives. Comparing to O-glycosides, the 
C-glycosides are structurally more stable against acidic and enzymatic cleavage due 
to the existence of their C–C glycosidic bond. Bristol-Myers Squibb [13] and Koto-
buki [14] disclosed C-aryl glucosides in 2001, which appear to have potent inhibi-
tion and good stability in vivo.
Many efforts devoted to develop carbohydrate-based therapeutics aim at finding 
inhibitors of glycoprocessing enzymes and discovering their structure–activity rela-
tionships (SAR). In therapies of diabetes, sugar derived or glycomimetic structures, 
such as acarbose, miglitol, or voglibose, have been applied (Fig. 2) [15].
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In 2017, Bokor et al. presented a review [16] where they described the syntheses 
and diverse bioactivities of C-glycopyranosyl arenes and heteroarenes. They pro-
vided a classification of the preparative routes to these synthetic targets according to 
methodologies and compound categories. Several of these compounds display anti-
diabetic properties due to enzyme inhibition and are used in the pharmacological 
treatment of type 2 diabetes. Figure 3 shows the glycoside structures that are dis-
cussed in this article. O-Glycosides, N-glycosides, and C-glycosides as antidiabetic 
drugs have been described in the following sections.
2  O‑Glycosides as Antidiabetic Agents
It is known that an O-glycoside—natural product phlorizin (Fig. 4) can lower plasma 
glucose levels and improve insulin resistance by increasing renal glucose excretion 
[17]. However, its sensitivity toward hydrolysis by glucosidases, unselective inhi-
bition of both SGLTs (sodium glucose transporters), and unfavorable effects of its 
aglycon phloretin on other glucose transporters prevented this compound from use 
as an antidiabetic drug.
More recently, guava leaves have gained attention in the control of T2DM [18, 
19]. In 2013, Eidenberger and coworkers investigated in vitro the effect of extracts 
from Psidium guajava L. leaves containing the flavonol-glycoside components [20]. 
An ethanolic extract was prepared from dried, powdered leaves of guava and was 
found to contain seven main flavonol-glycosides, which were isolated by semi-pre-
parative HPLC and tested individually. All isolated flavonol-glycosides were tested 
for their antidiabetic potential. Peltatoside 1, hyperoside 2, isoquercitrin 3, and guai-
javerin 4 (Fig.  5) show an inhibitory effect 5–10 times higher than that obtained 
for the three other partially characterized flavonol-glycosides. It seems therefore that 
most of the inhibitory action of the guava extract is due to the four identified fla-
vonol constituents 1–4 [20].
In 2015, Diaz-Lobo et  al. [21] reported on the synthesis and biological evalu-
ation of O-glycoside—a selective inhibitor that consists of an azobenzene moiety 
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Fig. 2  Carbohydrate derivatives and glycomimetic compounds in therapies of T2DM
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glycosidically linked to the anomeric carbon of a glucose molecule. The molecule 
incorporates an azobenzene photoswitch whose conformation can be significantly 
altered by irradiation with UV light. Synthesis of compound 9 (Scheme 1) started 
with the quantitative peracetylation of d-glucose 5 with acetic anhydride in pyri-
dine. Next, the anomeric acetyl group of 1,2,3,4,6-penta-O-acetyl-d-glucopyra-
noside 6 was selectively cleaved using benzylamine in THF to furnish 7 that was 
employed for the glycosylation of 4-hydroxyazobenzene by the Mitsunobu reaction. 
The resulting 4-(phenylazo)phenyl-2,3,4,6-tetra-O-acetyl-d-glucopyranoside 8 was 
deacetylated with MeONa/MeOH to give 4-(phenylazo)phenyl-d-glucopyranoside 
9. The azoglucoside 9 was obtained as a mixture of the α and β anomers. UV light 
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Fig. 3  O-Glycosides and N-, C-glycosyl antidiabetic molecules that are discussed in this review
Fig. 4  Structure of the natural 
product phlorizin
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induced E→Z photoisomerization of the azobenzene glucoside 9 was observed. 
In the ground state, the more stable (E)-isomer of the azobenzene glucoside 9 had 
a slight inhibitory effect on rat muscle GP (RMGP,  IC50 = 4.9  mM) and Escheri-
chia coli GS (EcGS,  IC50 = 1.6 mM). After irradiation and subsequent conversion 
to the (Z)-form, the inhibitory potency of the azobenzene O-glucoside did not sig-
nificantly change for RMGP  (IC50 = 2.4  mM), while its effect on EcGS increased 
50-fold  (IC50 = 32 μM). Although compound 9 was synthesized as a 1:4 mixture of 
the α- and β-anomers, analysis suggested that the more abundant β-anomer is the 
one responsible for the observed inhibition. So, Diaz-Lobo et  al. showed that the 
ability to selectively photocontrol the catalytic activity of key enzymes of glycogen 
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Fig. 5  Structures of the flavonol-glycosides: peltatoside 1, hyperoside 2, isoquercitrin 3, guaijaverin 4 
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Scheme 1  Synthesis of 4-(phenylazo)phenyl-d-glucopyranoside 9 [21]
 Topics in Current Chemistry (2019) 377:19
1 3
19 Page 8 of 84
metabolism might represent a new approach for the treatment of glycogen metabo-
lism disorders [21].
Functional foods can be used alone or in combination with existing therapies in 
preventing and treating type 2 diabetes. Trans-2,3,5,4′-tetrahydroxystilbene 2-O-β-
glucopyranoside (trans-THSG) 10 (Fig.  6), a dominant bioactive compound from 
Polygonum multiflorum (PM), has attracted increasing research interests due to 
its strong antioxidant activity. The content of naturally occurring cis-THSG (cis-
2,3,5,4′-tetrahydroxystilbene 2-O-β-glucopyranoside) 11 (Fig. 6) is very low in PM 
root, therefore W. Tang et al. prepared in 2017 cis-THSG by mimicking the tradi-
tional process of PM [22]. The anti-diabetic effects of trans- and cis-THSG were 
evaluated in type 2 diabetes. Cis-THSG 11 was found to be more effective than 
trans-THSG 10 in hypoglycemic effect [22].
Figure  7 presents information on the antidiabetic activity of O-glycosides dis-
cussed in Sect. 2. Below the structural formula of each inhibitor, the number of the 
compound and the scheme number on which it is located and the corresponding 
reference are provided. The most important information on the action of a given 
compound as a specific inhibitor is also included. Analyzing the structure of the 
compounds shown in Fig. 7, it can be seen that the phenyl groups are a structural 
element that is repeated in each compound. In the case of three compounds, they are 
phenolic derivatives. An interesting approach to the issue of active inhibitor struc-
ture is the idea presented by Diaz-Lobo and coworkers [21], in which they turned 
their attention to the ability to selectively photocontrol the catalytic activity of key 
enzymes of glycogen metabolism.
3  N‑Glycosides as Antidiabetic Agents
3.1  N‑(β‑d‑Glucopyranosyl) Amides and N‑(β‑d‑Glucopyranosyl)‑Urea Derivatives
Since O-glycosides are usually hydrolytically unstable, many carbohydrate ana-
logues such as N- or C-glycosides have been synthesized as therapeutic agents. 
Inhibition of GP is one of several intensively investigated approaches to find 
novel treatments for type 2 diabetes mellitus. Some N-glycosides such as N-(β-d-
glucopyranosyl) amides 12–14 (Fig.  8) were examined as inhibitors of GP [23]. 
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Fig. 6  Structures of trans-THSG 10 and cis-THSG 11 [22]
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N-(β-d-glucopyranosyl)-N’-acyl urea derivatives 15 and 16 are also inhibitors of GP. 
Compound 17 represents the most efficient glucose analogue inhibitor [24].
In 2004, Gyorgydeak et  al. transformed 2,3,4,6-tetra-O-acetyl-β-d-
glucopyranosyl- and 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-d-glucopyranosyl 
azides 18 into the corresponding per-O-acetylated N-(β-d-glycopyranosyl) amides 
19 by Staudinger protocol (Scheme 2) [25]. Removal of the protecting groups car-
ried out by Zemplén deacetylation furnished compounds 20. Compounds 19 and 20 
were tested against rabbit muscle glycogen phosphorylase. The best inhibitor of this 
series was N-(β-d-glucopyranosyl) 3-(2-naphthyl)-propenoic amide (Ki = 3.5 μM). It 
was shown that the acyl urea moiety is essential for the strong inhibition. A prop-
erly positioned and large enough hydrophobic group attached to the amide moiety 
makes the inhibition one order of magnitude stronger than that of the best amide 
inhibitor known earlier [N-(β-d-glucopyranosyl) acetamide 12, Fig.  8]. However, 
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Fig. 7  Antidiabetic activity of O-glycosides described in Sect. 2
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N-(β-d-glucopyranosyl) 3-(2-naphthyl)-propenoic amide is still much less efficient 
than the best-known inhibitor urea derivative 17 (Ki = 0.4 μM) [25].
In 2006, Czifrak et  al. used extension of the modified Staudinger methodology 
to the synthesis of N-(β-d-glucopyranosyl) monoamides of various dicarboxylic 
acids [26]. Such compounds offer the possibility to place a strongly polar group 
(COOH) at different distances from the sugar moiety while the ability to form the 
important H-bond from the amide can be maintained. O-Peracetylated N-(β-d-
glucopyranosyl)imino trimethylphosphorane obtained in  situ from 2,3,4,6-tetra-O-
acetyl-β-d-glucopyranosyl azide 21 and  PMe3 (Scheme  3) was reacted with satu-
rated and unsaturated aliphatic and aromatic dicarboxylic acids, or their anhydrides, 
or monoesters to give the corresponding N-(β-d-glucopyranosyl) monoamides of 
dicarboxylic acids or derivatives (e.g., derivative 23, Scheme 3). The acetyl protect-
ing groups were removed according to the Zemplén protocol to give a series of com-
pounds, which were moderate inhibitors against rabbit muscle glycogen phosphory-
lase b. The best inhibitor was 3-(N-β-d-glucopyranosyl-carbamoyl) propanoic acid 
23 (n = 2) with Ki = 20 μM [26].
In 2008, Somsak et  al. showed that the synthesis of the highly efficient glyco-
gen phosphorylase inhibitors N-(β-d-glucopyranosyl)-N′-substituted ureas has been 
significantly improved by using of glucopyranosylammonium carbamate [27]. This 
compound allowed the preparation of N-(β-D-glucopyranosyl)-N′-substituted ureas, 
-thioureas and selenourea 27 in two steps from d-glucose 24 (Scheme 4).
In 2012, Nagy et  al. synthesized N-(4-substituted-benzoyl)-N′-(β-
d-glucopyranosyl) urea derivatives 32 by addition of O-peracetylated 
O
OAc
AcO
AcO N3
R1
R1 = OAc, NHAc
18 19, 20
19 R1 = OAc, NHAc, R3 = Ac
20 R1 = OH, NHAc, R3 = H
NaOMe
MeOH
O
OR3
R3O
R3O NHCOR2
R1
1. Me3P, Me-C6H5, DCM
2. R2COX
21-88 %
X = OH, Cl, OCOCH3
R2 = Me, CF3, C6H5, NH2, NHCOMe, NHCOPh,
NHCOC10H7 (2-naphthyl), n-C5H11, n-C11H23, Me3C,
1-adamantyl, C6H5CH2, (C6H5)2CH, C6H5CH2CH2
C6H5CH=CH, 4-Me-C6H4, 4-C6H5-C6H4, 1-naphthyl,
2-naphthyl, C10H7CH=CH (2-naphthyl),
3,4,5-(MeO)3-C6H2, 4-Cl-C6H4-OCH2
C6H5C C Me
BocNH
H
BnO2C CH2
NHBoc
17-99 %
Scheme  2  Synthesis of N-(β-d-glucopyranosyl)- and N-(2-acetamido-2-deoxy-β-d-glucopyranosyl) 
amides 20 [25]
AcO
AcO
O
OAc
OAc
N3
1. Me3P
O
O
O
(CH2)n2.
NaOMe
MeOH
O
N
O
(CH2)nAcO
AcO
O
OAc
OAc
HO
HO
O
OH
OH
NH
O
(CH2)n CO2H
21 22 23
n = 2, 3, 4
Scheme 3  Synthesis of N-(β-d-glucopyranosyl) monoamides 23 of various dicarboxylic acids [26]
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β-d-glucopyranosylamine 28 to acyl-isocyanates 29 and subsequent deprotec-
tion (Scheme  5) [28]. Some compounds 32 were obtained by reactions of β-d-
glucopyranosylammonium carbamate 31 with acyl-isocyanates 29. Most of the new 
compounds 32 were low micromolar inhibitors of rabbit muscle glycogen phos-
phorylase b. There was no significant improvement of the inhibitory efficiency for 
N-(4-substituted-benzoyl)-urea 32 in comparison to N-benzoyl-urea. These results 
indicated the lack of a specific and crucial interaction from four position in phenyl 
ring within the catalytic site. The best inhibitors were compounds 32 with substitu-
ents R=4-CH3–C6H4 (Ki = 2.3 μM) and R=4-NO2–C6H4 (Ki = 3.3 μM) [28].
In 2012, Konya et  al. synthesized new glucose derivatives for the inhibi-
tion of GP [29]. They have reported on the synthesis and enzymatic evaluation 
of a series O-peracetylated N-(β-d-glucopyranosyl)-carboxamides with isoxa-
zole or 1,2,3-triazole rings. In a DCC-mediated coupling 2,3,4,6-tetra-O-acetyl-
β-D-glucopyranosylamine 34 and propiolic acid gave N-propynoyl-2,3,4,6-tetra-
O-acetyl-β-d-glucopyranosylamine 35, which was transformed by 1,3-dipolar 
cycloadditions with aromatic azides and nitrile-oxides to the corresponding O-per-
acetylated N-(β-d-glucopyranosyl)-1-substituted-1,2,3-triazole-4-carboxamides 36 
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and N-(β-d-glucopyranosyl)-3-substitutedisoxazole-5-carboxamides 38, respectively 
(Scheme 6). These compounds were O-deacetylated by Zemplén protocol to com-
pounds 37 and 39, which were tested as inhibitors of rabbit muscle glycogen phos-
phorylase b. Deacylated compounds 37 and 39 inhibited rabbit muscle glycogen 
phosphorylase b in the low micromolar range. The best inhibitors of the two series 
were N-(β-d-glucopyranosyl)-1-(3,5-dimethyl-phenyl)-1,2,3-triazole-4-carboxamide 
37 (Ar=3,5-di-Me-C6H3, Ki = 34  μM) and N-(β-d-glucopyranosyl)-3-(indol-2-yl)-
isoxazole-5-carboxamide 39 (Ar=indol-2-yl, Ki = 164 μM).
In 2014, Parmenopoulou and coworkers reported the in silico screening in the 
Zinc database of 1888 N-acyl-β-d-glucopyranosylamines as potential GP inhibi-
tors [30]. Six selected candidates from the screening were then synthesized and 
their inhibitory potency was assessed both in vitro and ex vivo. The direct acyla-
tion of 2,3,4,6-tetra-O-acetyl-β-d-glucopyranosylamine 41, easily prepared from the 
per-O-acetylated β-d-glucopyranosyl azide 40 upon catalytic hydrogenation, with 
a diverse set of commercially available acyl chlorides RCOCl, furnished the pro-
tected N-acyl-β-d-glucopyranosylamines 42. Removal of the acetyl groups of the 
derivatives 42, performed either by saturated methanolic ammonia or by the Zem-
plén method yielded analogues 43 (Scheme 7). Their inhibition constants’ values Ki 
in vitro ranged from 5 to 377 μM while two of them were effective at causing inacti-
vation of GP in rat hepatocytes at low μM concentrations [30].
Figure  9 presents the best GPb inhibitors from the N-(β-copper-catalyzed 
azide–alkyne cycloaddition-glucopyranosyl) amides and N-(β-d-glucopyranosyl)-
urea derivatives described in Sect. 3.1. The structural formula of each inhibitor, the 
number of the compound, the scheme number and the corresponding reference are 
provided. In the figure, the inhibitors are arranged in order from the strongest char-
acterized by the lowest inhibitory constant Ki value to the weaker one with the high-
est Ki value. It can be seen that all inhibitors accumulated in Fig. 8 are derivatives of 
glucose and compound 17 represents the most efficient glucose analogue inhibitor.
O
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Scheme  6  Synthesis of N-(β-d-glucopyranosyl)-1-substituted-1,2,3-triazole-4-carboxamides 37 and 
N-(β-d-glucopyranosyl)-3-substituted-isoxazole-5-carboxamides 39 [29]
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3.2  1,2,3‑Triazolyl N‑Glycosides
The medicinal importance of triazoles is due to their bioisosterism with peptide 
bonds as they can actively participate in hydrogen bonding, and due to their strong 
dipole moments, the triazoles are extremely stable to hydrolysis and oxidative/
reductive conditions. In 2011, Anand and coworkers described an efficient synthe-
sis of 1,2,3-1H-triazolyl glycohybrids with two sugar units via copper-catalyzed 
azide-alkyne cycloaddition (CuAAC) [31]. Potential inhibitors were prepared by a 
1,3-dipolar cycloaddition of glycosyl azides 47 and 49 to 2,3-unsaturated alkynyl 
glycosides 46 (Scheme  8). The synthesized glycohybrids were screened for their 
α-glucosidase, glycogen phosphorylase, and glucose-6-phosphatase inhibitory 
H2, 10% Pd/C, EtOH
20oC, 24h
DMF, RCOCl
Et3N, rt, 1h
NH3/MeOH or
NaOMe/MeOH
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AcO N3
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O
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41
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O
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Scheme 7  Synthesis of N-acyl-β-d-glucopyranosylamines 43 [30]
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Sect. 3.1
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activities. A few of the glycohybrids showed promising inhibitory activities against 
these enzymes [31].
In 2014, Goyard et al. examined CuAAC between acetylated β-d-glucosyl azide 
51 and alkyl or phenyl acetylenes 52, which led to the corresponding 4-substituted 
1-glucosyl-1,2,3-triazoles 54 (Scheme 9) [32]. 5-Halogeno analogues 56 were pre-
pared in similar conditions but with 2 equiv CuI or CuBr. In reactions with two equiv 
CuCl and either propargyl acetate or phenyl acetylene, the major products 59 dis-
played two 5,5′-linked triazole rings resulting from homocoupling of the 1-glucosyl-
4-substituted 1,2,3-triazoles (Scheme 10). The cycloaddition of 51 and 52 afforded 
four different products 53, 55, 57, and 59 with only minor amounts of the expected 
chlorinated derivatives 55 and with the dimeric products 59 being isolated as the 
major component. The two 4-phenyl substituted structures of compound 59 were 
unambiguously identified as atropisomers with aR stereochemistry. All O-unpro-
tected derivatives (Schemes 9, 10) were tested as inhibitors of GP. The modest inhi-
bition activities measured showed that 4,5-disubstituted 1-glucosyl-1,2,3-triazoles 
81-87 %
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bind weakly to the enzyme. This suggests that such ligands do not fit the catalytic 
site or any other binding site of the GP [32].
In order to gain additional data for structure–activity studies of the inhibition gly-
cogen phosphorylase, in 2015 Goyard et  al. prepared a series of eight GP inhibi-
tor candidates from peracetylglucopyranosyl azide 61 by 1,3-dipolar cycloaddition 
(Scheme 11) [33]. The need for a N-Boc-protected propargylamine was identified in 
the CuAAC with azide 61 under Meldal’s conditions, while Sharpless’ conditions 
were better adapted to the CuAAC of azide 61 with propargyl bromide. Cycloaddi-
tion of Boc-propargylamine with azide 61 afforded the N-Boc precursor of a 4-ami-
nomethyl-1-glucosyl-1,2,3-triazole 62, which gave access to a series of amide and 
sulfonamide derivatives (Scheme 11). The Boc-protected amine 62 was converted 
to the free amine 64, which were functionalized with acyl chlorides  R2COCl afford-
ing the amides 67. The amine 64 was also converted to the sulfonamide derivative 
69 using p-toluenesulfonyl chloride TsCl. The sulfonamide 70 was synthesized in 
order to take advantage of hydrophobic contact in the β-channel of GP and also to 
have potential additional contacts with the sulfonamide group and the side chain 
amino acids of the enzyme. Arbuzov reaction of the brominated derivative 71 with 
triethylphosphite under microwave activation allowed for formation of the acetylated 
phosphonate 72, which was converted to phosphonate 73 (Scheme 11). Enzymatic 
studies revealed poor to moderate inhibitions of deacetylated derivatives toward 
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glycogen GP. The N-Boc-protected amine 63 was the best inhibitor  (IC50 = 620 μM) 
unexpectedly slightly better than the 2-naphthylamido 68 substituted analogue 
 (IC50 = 650 μM) [33].
SGLT2 (sodium-dependent glucose co-transporter 2) is a glucose transporter that 
is responsible for 90% of the renal glucose reabsorption. For the treatment of type 
2 diabetes, suppression of glucose reabsorption through the inhibition of SGLT2 is 
a promising therapeutic approach. Therefore in 2015, Bai et  al. developed a con-
venient approach to the synthesis of novel triazole-N-glycoside derivatives 78 via 
CuSCN-catalyzed click reaction and Ullmann-type coupling reaction (Scheme 12) 
and examined the SGLT2 inhibitory activities of prepared N-glycosides [34]. For 
carbohydrate azides 74: glucosyl azide, galactosyl azide, ribosyl azide and amino-
glucosyl azide, reactions were performed and the triazole-N-glycosides 76 were gen-
erated with high selectivity, while mannosylazide and lactosyl azide showed moder-
ate selectivity (side product 77). After the successful construction of [6] ring-fused 
triazole-N-glycosides, the preparation of [6, 7] or [6, 8] ring-fused triazole-N-glyco-
sides via this protocol was also tried. Deprotection was carried out in the presence 
of  BCl3 or 1,2-diaminoethane and finally the acetyl-containing N-glycosides were 
treated with sodium methoxide to obtain the corresponding target compounds 78 
and side product 79 (Scheme 12). The SGLT2 inhibitory activities of N-glycosides 
78 were evaluated and some compounds showed moderate SGLT2 inhibition activi-
ties at 100 nM [34].
3.3  Other N‑Glycosides
In 2016, Chu et al. investigated the effect of C6-substitution on inhibition of SGLT2 
by N-indolylglucosides 83 (Scheme  13) [35]. As they investigated in a previous 
article [36], results suggested that the C6 position of the sugar moiety may play a 
critical role in the suppression of SGLT2. Therefore, Chu et  al. led optimization 
of N-glycosides proceeded via modification at the C6 position only, the aglycone 
unit 4-chloro-3-(4-cyclopropylbenzyl)-1H-indole being fixed. N-Indolylglucosides 
83 were prepared according to a synthetic method depicted in Scheme  13, using 
N-indolylglucoside 80 as the starting material. Treatment of 80 with methanesulfo-
nyl chloride (MsCl) in pyridine gave the corresponding 6-OMs N-glycoside, which 
was sequentially reacted with sodium azide  (NaN3) to afford the 6-azido compound 
81. Next, the synthesis of amides 83 was carried out via the amine 82, generated 
by the reduction of azido group in 81 with Zn/AcOH in THF. Amine 82 underwent 
direct amide bond formation with a variety of acyl chlorides to furnish 6-amide 
derivatives 83 (Scheme 13). After SAR study 6-amide derivatives 83 (R=acetyl and 
3-methoxy-3-oxopropanoyl) were identified as potent SGLT2 inhibitors. The data 
obtained indicated that 83 (R=acetyl and 3-methoxy-3-oxopropanoyl) are mildly 
to moderately selective for SGLT2 over SGLT1. Both compounds were also evalu-
ated in a urinary glucose excretion test and pharmacokinetic study. Compound 83 
(R=acetyl) was found capable of inducing urinary glucose excretion in rats [35].
A key point for the design of efficient drugs is the characterization of the inter-
actions governing its binding to the enzyme. In 2017, Mamais et al. designed and 
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prepared a glucose-based acridone derivative (GLAC), which is a potent inhibitor 
of GP and it allows probing subtle interactions in catalytic site [37]. The design of 
a catalytic site inhibitor was based on C-4 modification of β-d-glucopyranosyluracil 
and introducing of flat aromatic substituent, which can increase the binding affinity 
in the β-channel. Authors utilized an acridone moiety as a possible chromophore 
as well as fluorophore. β-d-Glucopyranosyluracil 84 was converted to 4-triazolyl 
derivative 85 and next substitution of 85 by 2-aminoacridone provided the protected 
adducts 86 (Scheme  14). Final deprotection furnished desired product GLAC 87. 
Authors reveal that the part of the catalytic site of GP behaves as a highly basic envi-
ronment in which GLAC 87 exists as a bis-anion. Authors reassumed that solvent 
structure of GLAC and the water-bridged hydrogen bonding interactions formed 
with the catalytic site residues in the β-channel are responsible for the observed inhi-
bition potency [37].
Figure 10 shows inhibitory properties of the best GPb and SGLT inhibitors from 
the N-glycosides: 1,2,3-triazolyl N-glycosides, N-indolylglycosides, and N-uracil 
glycoside presented in Sects. 3.2 and 3.3. The GLAC compound 87 is one of the 
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Scheme 14  Synthesis of GLAC 87  (N1-(β-d-glucopyranosyl)-N4-[2-acridin-9(10H)-onyl]-cytosine) [37]
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best GPb inhibitors described so far (Ki 31 nM). All compounds are derivatives of 
glucose. The presence of the cyclopropane ring in the structure of two of the active 
inhibitors is also noteworthy.
4  C‑Glycosides as Antidiabetic Agents
4.1  Aromatic C‑Glycosyl Derivatives
C-Glycosides are more metabolically stable than O-glycosides and tend to have 
higher oral bioavailability and plasma exposure without needing to be converted to 
a prodrug [4]. Among C-glycosyl derivatives, C-glycosylarenes have attracted much 
attention. In 2007, Praly et al. underwent kinetic and X-ray crystallographic study of 
two enzyme complexes of rabbit muscle unphosphorylated glycogen phosphorylase 
b (GPb) with ligands of the C-glucosylbenzo(hydro)quinone type [38]. The synthesis 
of quinones was accomplished from C-β-d-glycopyranosyl-1,4-dimethoxybenzenes 
89, which were prepared by reaction of penta-O-acetyl-β-d-glycopyranoses 88 
and 1,4-dimethoxybenzene (Scheme  15). Next, compounds 89 were converted to 
the corresponding C-glycosylhydro and C-glycosylbenzoquinones, with either an 
acetylated or deprotected sugar moiety. C-β-d-Glucosylbenzoquinone 91  (R1=H, 
 R2=OH) and C-β-d-glucosylhydroquinone 95  (R1=H,  R2=OH) (Scheme  15) were 
found to be competitive inhibitors of rabbit muscle GPb with Ki values of 1.3 and 
0.9  mM, respectively. In order to elucidate the structural basis of inhibition, the 
authors determined the crystal structures of 91 and 95 in complex with GPb. The 
complex structures reveal that the inhibitors can be accommodated at the catalytic 
site at approximately the same position as α-d-glucose and stabilize the transition 
state conformation of the 280 s loop by making several favorable contacts to Asp283 
and Asn284 of this loop [38].
Protein tyrosine phosphatase 1B (PTP1B) has recently been identified as a 
new drug target for type 2 diabetes [39]. In 2008. Lin et  al. synthesized β-C-
glycosiduronic acid quinones and β-C-glycosyl compounds as sugar-based PTP1B 
inhibitors [40]. To prepare 2-carbamoylbenzoic acid derivatives 100 (Scheme  16) 
and 106 (Scheme 17), β-C-aryl glucosides 96 and 102 were first tritylated at 6-posi-
tion, followed by protection of secondary hydroxyl function as benzoyl ester. 
To avoid intramolecular transesterification reaction, detritylation has been real-
ized under acidic condition with TFA to afford 98 and 104. The 6-hydroxy group 
was transformed into azide via mesylate. Staudinger protocol was then employed 
to convert azido sugars to carbamoylbenzoic acid derivatives. Reaction of 99 with 
phthalic anhydride led to a mixture of the desired compound 100 and N-phthalim-
ide derivative 101 (Scheme 16). Treatment of 105 with phthalic anhydride in THF 
afforded 106 (Scheme  17). Benzoyl protected quinone derivatives as well as aryl 
β-C-glycosyl compounds showed  IC50 values of 0.77–5.27 μM against PTP1B, with 
compounds 100 and 106 bearing an acidic function being the most potent [40].
In 2008, Meng et al. discovered dapagliflozin, selective renal sodium-dependent 
glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes [41]. 
Synthesis of dapagliflozin started from Friedel–Crafts acylation of phenetole with 
 Topics in Current Chemistry (2019) 377:19
1 3
19 Page 22 of 84
AcO
R2
O
OAc
OAc
R1 OAc
HO
R2
O
OH
R1 OH
OMe
OH
Cl
R1 = H, R2 = OAc
R1 = OAc, R2 = H
R1 = H, R2 = OH
R1 = OH, R2 = H
88
92
AcO
R2
O
OAc
R1 OAc
O
O
R1 = H, R2 = OAc
R1 = OAc, R2 = H
93
AcO
R2
O
OAc
R1 OAc
OMe
OMe
R1 = H, R2 = OAc
R1 = OAc, R2 = H
89
OMe
OMe (2 equiv.)
SnCl4 (3 equiv.)
CF3CO2Ag (1.5 equiv.)
CH2Cl2, 25-30
oC, 5h
HO
R2
O
OH
R1 OH
OMe
OMe
AcO
R2
O
OAc
R1 OAc
OH
OH
R1 = H, R2 = OH
R1 = OH, R2 = H
R1 = H, R2 = OAc
R1 = OAc, R2 = H
90
94
HO
R2
O
OH
R1 OH
O
O
HO
R2
O
OH
R1 OH
OH
OH
R1 = H, R2 = OH
R1 = OH, R2 = H
R1 = H, R2 = OH
R1 = OH, R2 = H
91
95
CAN (3 equiv.), H2O, rt, 30 min
CAN (3 equiv.)
CH3CN/H2O 1:1, 25 min
0.5% AcCl in MeOH
1 week, rt
NaBH4 (2 equiv.)
EtOAc, rt, 30 min
0.1M or 0.033M MeONa
MeOH, rt, 2h
or
1% AcCl in MeOH, 5d, rt
Ag2O, propan-2-ol, rt, 2h
or
PhI(OAc)2 (1.5 equiv), MeOH, rt, 40 min
69-81 %
> 95 %
76-79 %
84-93 %
88-91 %
80-100 %
80-94 %
MeOH/NEt3/H2O 8:1:1, rt, 10-12h
or
MeONa/MeOH, rt, 2h
Scheme 15  Synthesis of C-β-d-glucosylbenzoquinones 91 and C-β-d-glucosylhydroquinones 95 [38]
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5-bromo-2-chlorobenzoyl chloride, which was formed from 5-bromo-2-chloroben-
zoic acid 107 in reaction with oxalyl chloride (Scheme 18). Reduction of p-benzo-
phenone 108 by triethylsilane and  BF3·OEt2 provided aglycon 109. Lithium halogen 
exchange, followed by the addition of the nascent lithiated aromatic to 110, gave a 
mixture of lactols, which were converted in situ to the desilylated O-methyl lactols 
111 by treatment with methanesulfonic acid in methanol. Reduction of the anomeric 
methoxy group of 111 using triethylsilane and  BF3·OEt2, followed by peracetylation, 
yielded tetraacetate 112. Hydrolysis of 112 with lithium hydroxide generated 113 
(Scheme 18). Authors resumed that dapagliflozin 113 is a potent, selective SGLT2 
inhibitor that is not subject to O-glucosidase degradation. Compound 113 is a much 
more potent stimulator of glucosuria in normal rats than other SGLT2 inhibitors. 
The promising significant reduction of blood glucose levels in diabetic rats prompted 
further evaluation of 113 in the clinic for the treatment of type 2 diabetes [41].
In 2010, Kato and Kawabata synthesized an isoflavone C-glucoside puerarin and 
several derivatives, which were candidate for treatment of diabetes mellitus [42]. 
Treatment of TMSOTf to the mixture of glucosyl imidate 114 and an acetophenone 
115 afforded a C-glucoside 116 (Scheme 19). Group 6-OH of compound 116 was 
selectively protected by a benzyl group. Aldol condensation of 117 with an aldehyde 
118 gave chalcones 119. Compounds 119 were treated with Tl(NO3)3 and heated 
in an acidic medium to form isoflavone structure 120. The benzyl group protecting 
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2. BzCl
TFA, CH2Cl2
H2O
1. MsCl, TEA
2. NaN3, DMF
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Scheme 17  Synthesis 2-carbamoylbenzoic acid derivative of β-C-glycosyl compound 106 as sugar-based 
PTP1B inhibitor [40]
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OH was selectively removed and after trifluoromethanesulfonylation and subse-
quent reaction with Pd(OAc)2 derivative 121a was prepared. Finally, benzyl groups 
were removed by treatment with  BBr3 to give puerarin 122 in 13% overall yield and 
regioisomer of 122, genistein 6-C-glucoside 123 (Scheme 19). The compound 122 
was applied for the structure–activity relationship study. The results of research indi-
cated that the C-glucoside part of the compound 122 was not much involved in the 
activity. The structure responsible for the glucose uptake enhancing activity was the 
isoflavone moiety. However, the C-glucose may involve in physical properties of 122 
and raises solubility in water [42].
In 2010, Nomura et  al. discovered that C-glucosides bearing heterocyclic 
ring formed metabolically more stable inhibitors for sodium-dependent glu-
cose cotransporter 2 (SGLT2) than the O-glucoside [43]. To synthesize appropri-
ate compounds, aglycones 124 were dissolved in tetrahydrofuran and toluene, and 
treated with n-butyllithium at − 78  °C to generate aryllithium, followed by addi-
tion of 2,3,4,6-tetra-O-trimethylsilyl-β-d-gluconolactone (Scheme  20). The result-
ing anomeric mixture of lactols was converted into desilylated methyl ethers 125 
by addition of methanesulfonic acid in methanol. C-Glucoside derivatives 126 were 
obtained by stereoselective reduction of 125 using a combination of triethylsilane 
and boron trifluoride etherate in methylene chloride. Thiophene derivative 126 
canagliflozin  (R1=Me in the para position relative to glucose moiety, Het=tiophene 
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Scheme 19  Synthesis of puerarin 122 and its regioisomer 123 [42]
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with  R2=C6H4-4-F in position 2) was a highly potent and selective SGLT2 inhibi-
tor and showed pronounced anti-hyperglycemic effects in high-fat diet-fed mice 
 (IC50 = 2.2  nM). Canagliflozin is the first SGLT2 inhibitor to be approved in the 
USA and is under regulatory review in the EU [44, 45].
In 2011, Xu and coworkers synthesized a series of C-aryl glucosides with vari-
ous substituents at the 4′-position of the distal aryl ring and evaluated for inhibi-
tion of human hSGLT1 and hSGLT2 [46]. Scheme  21 depicts the construction 
of aglycone 132, which is a part of bexagliflozin 134 selective SGLT2 inhibi-
tor that reached phase III clinical trials [47]. Friedel–Crafts acylation of benzene 
with the benzoyl chloride derived from benzoic acid 127 by treatment with oxa-
lyl chloride provided the corresponding benzophenone 128, which were reduced 
by triethylsilane in the presence of TFA and catalytic trifluoromethanesulfonic 
acid to generate bromodiarylmethane 129. Finally, aglycone 132 was constructed 
by vinyl ether formation of the alcohol 130 with vinyl acetate in the presence 
of sodium carbonate and a catalytic amount of [IrCl(COD)]2 (Scheme 21). Lith-
ium-bromide exchange of bromodiarylmethane 132 and addition of the resulting 
aryllithium to 2,3,4,6-tetra-O-trimethylsilyl-d-gluconolactone 133 followed by 
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etherification with methanol in the presence of methylsulfonic acid provided desi-
lylated O-methyl lactols, which were reduced with triethylsilane and  BF3.OEt2 
to give desired C-aryl glucoside 134. The  IC50 values for bexagliflozin against 
human SGLT1 and SGLT2 are 5.6 μM and 2 nM, respectively [47].
In 2012, Imamura and coworkers discovered a novel benzothiophene deriva-
tives 139, among them ipragliflozin  (R1=H,  R2=F), which are a highly potent 
and selective SGLT2 inhibitors (Scheme  22) [48]. Lithiation of 135 followed 
by the addition of aromatic benzaldehydes, yielded alcohols those were reduced 
with  Et3SiH and  BF3.OEt2 to give aglycones 136. Lithium halogen exchange fol-
lowed by the addition of a lithiated aromatic to compound 137 yielded lactols 
those were reduced by treatment with  Et3SiH and  BF3 etherate to give compounds 
138. Successive removal of the benzyl groups generated compounds 139. Ipragli-
flozin  (R1=H,  R2=F) was a highly potent and selective human SGLT2 inhibitor 
 (IC50 = 7.4 nM).
Figure  11 contains the best inhibitors GPb, PTP1B, and SGLT2 having the 
aromatic C-glycoside structure that are described in Sect.  4.1. The analysis of 
the structure of the C-glycosyl derivatives presented in Fig.  11 shows that the 
presence of a chlorine or fluorine atom as well as the presence of sulfur-con-
taining heteroaromatic ring guarantees an increased antidiabetic activity of the 
compound. All inhibitors shown in Fig. 11 are derivatives of glucose. Thus, also 
taking into account the structures of previously presented the best inhibitors, it 
can be concluded that this glucose molecule guarantees high inhibitor activity. 
Referring to the structure of the best inhibitors shown in Fig. 10, it can also be 
concluded that the cyclopropane ring is a structural element that guarantees high 
inhibitor activity. The repeating structural element is also the 1,4-dihydroxy or 
dimethoxyphenyl system.
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Scheme 22  Synthesis of benzothiophene derivatives 139 selective SGLT2 inhibitors [48]
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4.2  Heteroaromatic C‑Glycosyl Derivatives
In 2001, Somsák et al. described highly chemo-, regio-, and stereoselective proce-
dure that allows for the preparation of d-gluco- and d-xylopyranosylidene-spiro-
hydantoins and thiohydantoins in six steps from the corresponding free sugar [49]. 
In the key step of the syntheses C-(1-bromo-1-deoxy-β-d-glycopyranosyl)forma-
mides 142 and 143 were reacted with cyanate ion to give spiro-hydantoins 144 
and 145 with a retained configuration at the anomeric center as the major products 
(Scheme 23). Thiocyanate ions gave spiro-thiohydantoins 144 with an inverted ano-
meric carbon as the only products. The acetylated compounds were deprotected by 
the Zemplen procedure. Enzyme assays with a and b forms of muscle and liver gly-
cogen phosphorylases showed spiro-hydantoin 144  (R1=CH2OH,  R2=H, X=O) and 
spirothiohydantoin 144  (R1=CH2OH,  R2=H, X=S) to be the best and equipotent 
inhibitors with Ki values in the low micromolar range. The study of epimeric pairs 
of d-gluco and d-xylo spiro-hydantoins and N-(d-glucopyranosyl)amides indicated 
the role of specific hydrogen bridges in binding the inhibitors to the enzyme [49].
In 2004, Somsak et al. have decided to prepare C-(β-d-glucopyranosyl) hetero-
cycles exhibiting acidic, basic, and neutral properties in the heterocyclic moieties 
O
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Fig. 11  Inhibitory properties of the best inhibitors from the aromatic C-glycosyl derivatives described in 
Sect. 4.1
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[50]. They transformed per-O-acetylated and -benzoylated β-d-glucopyranosyl 
cyanides 146 into the corresponding 5-(β-d-glucopyranosyl)tetrazoles 147, 
2-(β-d-glucopyranosyl)benzothiazoles 153 and 2-(β-d-glucopyranosyl)-
benzimidazoles 151 (Scheme  24). Acylation of the tetrazoles 147, either by 
acetic or trifluoroacetic anhydride, gave 5-(β-d-glucopyranosyl)-2-methyl- and 
-2-trifluoromethyl-1,3,4-oxadiazoles 148, respectively. Removal of the protect-
ing groups furnished inhibitors 147 (R=H), 149, 152, and 154 exhibiting inhibi-
tor constants in the micromolar range. The tetrazole 147 (R=H) ring of slightly 
acidic character was unfavorable for the binding of this compound to the GP 
enzyme. The neutral aglycones in 149 (Ki = 212  μM) and 154 (Ki = 229  μM) 
result in moderate inhibitors. The most efficient inhibitor was benzimidazole 152 
(Ki = 11 μM) [50].
In 2005, Chrysina et  al. examined inhibitors with enhanced affinity for glyco-
gen phosphorylase that might control hyperglycemia in type 2 diabetes [51]. Three 
analogs of β-d-glucopyranose: 2-(β-d-glucopyranosyl)-5-methyl-1,3,4-oxadiazole 
155, 2-(β-d-glucopyranosyl)-benzothiazole 156 and 2-(β-d-glucopyranosyl)-
benzimidazole 157 were examined (Fig. 12). The compounds showed competitive 
inhibition with Ki values of 145.2 μM, 76 μM and 8.6 μM, respectively. In order to 
establish the mechanism of this inhibition, crystallographic studies were carried out 
and the structures of GPb in complex with the three analogs were determined. The 
complex structures revealed that the inhibitors can be accommodated in the catalytic 
site of T-state GPb with very little change of the tertiary structure [51].
In 2010, Kang and coworkers designed and synthesized pyridazinyl and thiazolyl 
derivative of C-glycosides [52]. They wanted to check if replacement of the phe-
nyl ring with the corresponding heterocyclic ring could improve the GLT2 inhibi-
tor. As shown in Scheme 25, the lithiated thiazolylglucoside 158 was converted to 
5-chlorothiazolylglucoside or 5-bromothiazolylglucoside 159 by electrophilic halo-
genation using  CCl4 and  CBr4, respectively. Lithiation of 5-bromothiazole interme-
diate 159 was performed by treatment of LDA, and the resulting anion underwent a 
metal–halogen exchange reaction so that a bromine atom moved to a new position 
on the thiazole ring. The lithiated intermediate 160 was subjected to coupling with 
aldehydes to produce the desired products 161. The same conditions were applied 
to 5-chlorothiazole 159. The chlorine atom did not move to the 4-position but main-
tained the original position. The coupling reactions of 5-chlorothiazole intermediate 
159 with aldehydes produced 163. Both debenzylation and reduction were concur-
rently performed to prepare the final products 162 and 164 (Scheme 25). Introduc-
tion of the pyridazine ring at the anomeric carbon of d-glucopyranose was carried 
out in a stereoselective fashion [52]. Cyclization from γ-keto ester 165 to dihydro-
pyridazinone 166 was accomplished with hydrazine monohydrate (Scheme  26). 
Dihydropyridazinone 166 was oxidized to pyridazinone 167 using bromine under 
acetic acid. Pyridazinone 167 was converted to 6-chloro-5-benzylpyridazine 168 by 
treatment with  POCl3. Final removal of the four benzyl groups to produce the target 
compound 169 was accomplished with application TMSI (Scheme 26).
Biological activities of the compounds 162, 164 (Scheme  25) and 169 
(Scheme 26) were evaluated by in vitro SGLT2 inhibition assay. While dapagliflozin 
(Scheme 18) shows highly potent inhibitory activity against human hSGLT2, it was 
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discovered that neither pyridazinyl nor thiazolyl analogs improved hSGLT2 inhibi-
tion [52].
In 2010, Handlon and coworkers described a method of obtaining C-linked het-
erocyclic glucosides that could inhibit human SGLT2 [53]. The authors used the 
bromo heterocycles 170 and the glucal boronate 171 to obtain a series of benzi-
sothiazole- and indolizine-β-d-glucopyranosides 174 (Scheme  27). The key step 
of the reactions was a palladium-catalyzed cross-coupling leading to intermediates 
172. Subsequent hydroboration–oxidation reactions followed by an acidic deprotec-
tion of the sugar rings in the molecules of 173 provided the final products 174. The 
substrates 170 were obtained in three various ways, depending on their heterocyclic 
cores. The compounds were evaluated for their human SGLT1 and SGLT2 inhibi-
tion potential by monitoring the suppression of the uptake of 14C-labeled α-methyl-
d-glucopyranoside by COS-7 cells, which transiently expressed human SGLT2 or 
SGLT1, using BacMam technology [54]. The authors focused mostly on the influ-
ence of the character of the substituents  R1 and  R2 and the basicity of the aromatic 
core on the inhibition potential of the compounds. It was found that their oral 
absorptions were good enough to avoid a transformation into the corresponding pro-
drugs prior to the intake. Finally, the compound 174 (X=C, Y=S, Z=N,  R1=t-Bu, 
 R2=H) was found to be an inhibitor of SGLT2 with an  IC50 of 10 nM [53].
In 2012, Yao et al. based on previous research into usage of N-indolylxylosides as 
SGLT2 inhibitors [55] and knowledge about metabolic stability of the C-glycosidic 
bond, synthesized the C-indolylxylosides as a result of a five-step synthesis. It is 
noteworthy that their SAR studies disclosed the key role of two substituents in the 
indole moiety. The presence of both a distal p-cyclopropylphenyl group and substit-
uent in 7-position is necessary to achieve potent inhibitory activity. Using 2,3,4-tri-
O-benzyl-d-xylonolactone 175 and diverse 3-bromo-1-tosyl-1H-indoles 176 as a 
starting material in lithium halogen exchange reaction, a variety of lactols 177 were 
received. Reduction with trietylsilane and boron trifluoride etherate gave C-linked 
β-xylosides 178 (Scheme 28). During heating of the previously obtained compounds 
178 over KOH in THF/EtOH, detosylation took place, providing free indoles 179. 
Benzyl ether groups of 179 were removed under hydrogenolysis to furnish 180. 
Xylopyranosyl indoles 180 underwent N-alkylation with p-cyclopropylbenzyl bro-
mide and gave the final products 181. Evaluation of biological activity demonstrated 
that from among C-indolylxylosides, compound 181 (R=F) turned out to be the 
strongest and metabolically stable SGLT2 and SGLT1 inhibitor. In compliance with 
SAR studies bearing two groups most significant for inhibition activity, it exhib-
its an SGLT2  EC50 value of 47 nM and SGLT1  EC50 value of 282 nM. Moreover 
O
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OH
HO
HO
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N
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Fig. 12  2-(β-d-glucopyranosyl)-5-methyl-1,3,4-oxadiazole 155, 2-(β-d-glucopyranosyl)-benzothiazole 
156 and 2-(β-d-glucopyranosyl)-benzimidazole 157 [51]
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pharmacokinetic studies showed that molecule 181 (R=7-F) is metabolically stable 
after intravenous and oral administration to rats [55].
In 2012 Li et  al. designed and synthesized analogs of SGLT2 inhibitors con-
taining the 1,2,3-triazole motif [56]. Substituted 1,2,3-triazole is a very important 
building block for more complex bioactive compounds, such as tazobactam, antivi-
ral, anti-HIV, antibacterial, and antiallergic agents [56]. The C-glucosides with tria-
zole aglycone were constructed by click chemistry. The synthesis of the key alkyne 
intermediate is outlined in Scheme 29. Alkyne 187 was obtained from 2,3,4,6-tetra-
O-benzyl-d-glucopyranose 182 in five steps. 2,3,4,6-Tetra-O-benzyl-d-(+)-glucono-
1,5-lactone 183 was prepared by Swern oxidation of benzyl protected d-glucopyra-
nose 182. Trimethylsilylacetylene was deprotonated with n-BuLi and treated with 
lactone 183 to provide ketose 184. The free hydroxyl group was reduced and the 
trimethylsilyl group was removed easily by stirring in a mixture of NaOH, metha-
nol, and dichloromethane, yielding the benzyl-protected alkyne 186. Alkyne 186 
and azides were used directly to construct triazole aglycon by click chemistry. 
Compound 186 was transformed into the acetyl-protected form 187. Triazoles 188 
were then synthesized through CuAAC with the corresponding azides (Scheme 29). 
Finally, the acetyl protecting groups were removed to give the triazole-linked 
C-glycosides compounds 189. Most of the synthesized compounds demonstrated 
increased urinary glucose excretion in SD rats, but they increased urine volume to a 
lesser degree than that of dapagliflozin [56].
In 2013, Bokor et  al. elaborated a new method for the synthesis of 3-(β-d-
glucopyranosyl)-5-substituted-1,2,4-triazoles [57]. The starting compound was 
O-perbenzoylated β-d-glucopyranosyl formimidate 190, which reacted with tosyl-
hydrazide to give tosylamidrazone 191 (Scheme 30). 3-(β-d-Glucopyranosyl)-5-
substituted-1,2,4-triazoles 194 were prepared by acylation of O-perbenzoylated 
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N1-tosyl-C-β-d-glucopyranosyl formamidrazone 191 and subsequent removal 
of the protecting groups. The best inhibitor was 3-(β-d-glucopyranosyl)-5-(2-
naphthyl)-1,2,4-triazole 194 (Ki = 0.41 μM against rabbit muscle glycogen phos-
phorylase b).
In 2013, Sakamaki and coworkers described the synthesis and structure–activ-
ity relationship of thiophene-C-glucosides [58]. The synthetic route to thiophene-
C-glucosides 199 is shown in Scheme 31, based on the reaction of aryl halide 196 
with glucal-boronate ester 195. Coupling reaction with using dichlorobis (triph-
enylphosphine) palladium between aglycones 195 and glucal-boronate 196 gave 
197, followed by stereoselective hydroboration and oxidation in alkaline condi-
tions yielded 198 with the desired β-configuration. O-silyl groups of 198 were 
deprotected with tetra-n-butylammonium fluoride (TBAF) to afford thiophene-
C-glucosides 199 (Scheme  31). The human hSGLT2 inhibitory activities and 
rat urinary glucose excretion (UGE) effects of 199 were evaluated. As a result, 
O
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Scheme 30  Synthesis of 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-triazoles 194 [57]
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they showed good hSGLT2 inhibitory activities. In particular, the chlorothio-
phene derivative 199 showed remarkable inhibitory activity against hSGLT2 
 (IC50 = 4.0 nM) [58].
In 2014, Somsak et al. synthesized derivatives of d-xylose with aglycones of the 
most efficient glucose-derived inhibitors of glycogen phosphorylase to explore the 
specificity of the enzyme towards the structure of the sugar part of the molecules 
[59]. 2-(β-d-Xylopyranosyl)benzimidazole 204 (Scheme 32) and 3-substituted-5-(β-
d-xylopyranosyl)-1,2,4-triazoles 209 (Scheme 33) were obtained in multistep proce-
dures from O-perbenzoylated β-d-xylopyranosyl cyanide 200.
Cycloadditions of nitrile-oxides and O-peracetylated exo-xylal 212 obtained from 
the corresponding β-d-xylopyranosyl cyanide 210 furnished xylopyranosylidene-
spiro-isoxazoline derivatives 214 (Scheme 34) [59].
Oxidative ring closure of O-peracetylated β-d-xylopyranosyl-thiohydroximates 
prepared from 1-thio-β-d-xylopyranose 215 and nitrile-oxides gave xylopyrano-
sylidene-spiro-oxathiazoles 217 and 218 (Scheme  35) [59]. The fully deprotected 
test compounds 204, 209, 214, 219, and 220 were assayed against rabbit muscle gly-
cogen phosphorylase b. Evaluation showed very weak inhibition for 3-(2-naphthyl)-
5-(β-d-xylopyranosyl)-1,2,4-triazole 209 only, while all other compounds proved 
ineffective in a concentration of 625 μM. Observations showed that the aglycones 
rendering their glucose derivatives to nanomolar inhibitors are not yet capable of 
completely overriding the effect of losing the side chain of the glucose moiety [59].
Investigations on the inhibitory and binding properties of different monosac-
charides indicated the superior effectiveness of d-glucose [60, 61]. Changes in the 
sugar configuration as well as removal or replacement of substituents of the glucose 
moiety proved detrimental for the inhibition. Therefore, in 2015 Bokor et al. elabo-
rated synthetic methods for D-glucal attached to oxadiazoles by a C–C bond [62]. 
For the preparation of the target compounds 226, two main routes were used; the 
functionalized glucal 226 was made by the formation of the heterocycle in the final 
stage (Scheme 36) or the 1,2-double bond can be introduced into a preformed C-glu-
copyranosyl heterocycle 227 (Scheme  37). Introduction of the double bond was 
effected by either DBU induced elimination of benzoic acid from O-perbenzoylated 
glucopyranosyl precursors 221 (X=H) or Zn/N-methylimidazole mediated reduc-
tive elimination from the 1-bromoglucopyranosyl starting compounds 221 (X=Br) 
(Scheme  36). Test compounds 226 were obtained by Zemplen debenzoylation. 
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Unfortunately, none of these showed significant inhibition of rabbit muscle glycogen 
phosphorylase b, indicating that the binding of the aglycones was not strong enough 
to override the detrimental effects of the changes in the sugar parts of the molecules 
[62].
In 2016, Bokor et  al. designed various C-glucopyranosyl-1,2,4-triazolones as 
potential inhibitors of GP [63]. Syntheses of these compounds were performed with 
O-perbenzoylated glucose derivatives 228, 230, and 233 as precursors (Scheme 38). 
Boiling a solution of carbamoyl-C-β-d-glucopyranosyl formamidrazone 228 in 
m-xylene gave 3-β-d-glucopyranosyl-1,2,4-triazol-5-one 229. Cyclization of 230 
in boiling DMF produced the expected triazolone 231. Reaction of tosyl-C-β-d-
glucopyranosyl formamidrazone 233 with ethyl chloroformate furnished 3-β-d-
glucopyranosyl-1-tosyl-1,2,4-triazol-5-one 234 (Scheme  38). In  situ prepared 
β-d-glucopyranosylcarbonyl isocyanate 237 was transformed by PhNHNHBoc 
into 3-β-d-glucopyranosyl-1-phenyl-1,2,4-triazol-5-one 240, while the analogous 
1-(2-naphthyl) derivative 243 was obtained from the unsubstituted triazolone 242 
by naphthalene-2-boronic acid in a Cu(II) catalyzed N-arylation (Scheme 39). Test 
compounds were prepared by Zemplen deacylation. The new glucose derivatives had 
weak or no inhibition of rabbit muscle glycogen phosphorylase b. The best inhibi-
tor was 3-β-d-glucopyranosyl-1-(2-naphthyl)-1,2,4-triazol-5-one 244 (Ki = 80  μM) 
(Scheme 39) [63].
Glucose-based spiro-isoxazolines can be considered as anti-hyperglycemic agents 
against type 2 diabetes through GP inhibition. In 2016, d-glucopyranosylidene-
spiro-isoxazolines 252 were prepared by 1,3-dipolar cycloaddition of nitrile oxides 
249 generated in  situ to methylene exo-glucals 250 (Scheme  40) [64]. Reagents 
249 were generated by reaction of a sodium hypochlorite 246 and oximes 245. 
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Appropriate oximes 245 reacted also with NCS 247 and aryl α-chloroaldoximes 248 
were prepared. Hydrochloric acid elimination in the presence of  NEt3 afforded reac-
tive nitrile oxides 249. O-unprotected spiro-isooxazolines 252 were evaluated as GP 
inhibitors and exhibited  IC50 values ranging from 1 to 800 μM. The tetra-O-acety-
lated spiro-isoxazoline 251 bearing 2-naphthyl residue shoved a much lower value 
compared to that of the O-unprotected analog 252 [64]. The 2-naphthyl substituted 
glucopyranosylidene-spiro-isoxazoline 252 was the best compound identified in this 
study (GPb Ki = 0.63 μM).
Syntheses of a series of C-glucopyranosyl pyrroles, indole, and an improved prep-
aration of C-glucopyranosyl imidazoles allowed in 2016 Kantsadi et al. to study and 
compare their inhibitory efficiency against GP [65]. C-β-D-Glucopyranosyl pyrrole 
derivatives 258, 260, and 262 were prepared in the reactions of pyrrole 254, 2-aryl-
pyroles 255, and 3-aryl-pyrroles 256 with O-peracetylated β-d-glucopyranosyl 
trichloroacetimidate 253 (Scheme  41). (2β-d-Glucopyranosyl) indole 267 was 
obtained by a cross-coupling of O-perbenzylated β-d-glucopyranosyl acetylene 263 
with N-tosyl-2-iodoaniline 264 followed by spontaneous ring closure (Scheme 42) 
[65]. An improved synthesis of O-perbenzoylated 2-(β-d-glucopyranosyl) imi-
dazoles 270 was achieved by reacting C-glucopyranosyl formimidates 268 with 
α-aminoketones 269 (Scheme 43) [65]. The deprotected compounds were assayed 
with isoforms of glycogen phosphorylase to show no activity of the pyrroles 
258, 260, 262, and indole 267 against rabbit muscle GPb [65]. The imidazoles 
271 proved to be the best-known glucose-derived inhibitors of not only the mus-
cle enzymes (both a and b) but also of the pharmacologically relevant human liver 
hlGPa (Ki = 156 and 26 nM for the phenyl and 2-naphthyl derivatives, respectively). 
An X-ray crystallographic study of the rmGPb-imidazole complexes revealed struc-
tural features of the strong binding, and also allowed explaining the absence of inhi-
bition for the pyrrole and indole derivatives [65].
Figure 13 shows the structure of the best inhibitors from heteroaromatic C-glyco-
side derivatives described in Sect. 4.2. Again, the analysis of the structure of the best 
inhibitors leads to the conclusion that the highest activity is ensured by the presence 
of glucose as a structural element. Only in the case of compounds 181 and 209 is it 
xylose. It can also be seen that the high inhibitor activity is guaranteed by the pres-
ence of a structural element such as a five-membered heteroaromatic ring contain-
ing two or three nitrogen atoms. The high activity of the inhibitor is also ensured 
by the presence of such heteroaromatic rings as: 1,3,4-oxadiazole (compound 149), 
benzisothiazole (compound 174), indole (compound 181), thiophene (compound 
199), and isoxazoline (compound 252). Again, presents a distal p-cyclopropylphenyl 
group (compound 181) is necessary to achieve potent inhibitory activity. Also, the 
glycone and aglycone spiro combination (compounds 144) ensures high inhibitor 
activity.
4.3  Other C‑Glycosyl Derivatives
In 2009, Bisht and coworkers described the synthesis of aryl butenoyl C-glycosides 
277 by aldol condensation of peracetylated glycosyl acetones 275 with aromatic 
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aldehydes followed by deacetylation with methanolic NaOMe (Scheme  44) [66]. 
β-C-Glycosidic ketones 274 were prepared in one step directly from the unprotected 
sugar 272 and pentane-2,4-dione 273 under aqueous conditions by Knoevenagel 
condensation [67]. Compounds 275 on aldol reaction with different aldehydes under 
ambient reaction conditions resulted in (E)-4-aryl-1-(glycopyranosyl)-but-3-en-2-
ones 276 [68]. Prepared C-glycosides 277 were evaluated for their α-glucosidase, 
glucose-6-phosphatse, and glycogen phosphorylase enzyme inhibitory activi-
ties in  vitro and in  vivo. Three of the compounds 277 (Ar=2-naphthyl, phenyl, 
3,4-dimethoxyphenyl) showed potent enzyme inhibitory activities as compared to 
standard drugs such as acarbose and metformin. These C-glycosides caused a sig-
nificant decline in the hyperglycemia of the diabetic rats post sucrose-load [66].
Another approach for the inhibition of GP could take advantage of multiva-
lency. In 2009, Cecioni and coworkers examined influence multivalency for the 
inhibition of GP [69]. They synthesized two distinct trivalent inhibitors of GP 
through Cu(I)-assisted 1,3-dipolar cycloaddition and by formation of a trisoxa-
diazole derivative. The perbenzoylated glucosyl cyanide 278 was reacted with 
hydroxylamine hydrochloride in pyridine to afford the desired amidoxime 279 
(Scheme  45). The formation of the O-acyl-amidoxime 280 was achieved with 
4-pentynoic acid in the presence of EDCI/HOBt as coupling agents. The use of 
thermal activation combined with TBAF catalysis provided the cyclic oxadia-
zole 281. The alkyne-terminated oxadiazole 281 was then engaged in a Huisgen’s 
Cu(I)-catalyzed 1,3-dipolar cycloaddition reaction under microwaves activation 
with benzyl azide to afford 1,4-disubstituted 1,2,3-triazole 282. Debenzoylation 
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I
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of compound 282 afforded hydroxylated GP inhibitor candidate 283. The reaction 
of 1,3,5-tris(azidomethyl)benzene with the alkyne derivative 281 under micro-
wave activation and Cu(I) catalysis afforded the cycloadduct 284. The saponifi-
cation of the benzoate ester 284 provided the fully hydroxylated macromolecule 
285. Also, a more condensed trifunctional macromolecule was prepared in which 
the C-glucosyl-oxadiazole moiety was directly attached to a benzene ring. A bio-
logical study of the inhibiting properties of these trivalent inhibitors of GP have 
shown that the valency of the molecules influences slightly the inhibition of the 
enzyme, whereas the presence of a spacer arm between the core and the pharma-
cophore moieties does not. Authors reassumed that multivalent inhibitors were 
always superior to their monovalent counterparts [69].
In 2010, Kakinuma et al. gave considerable attention to 5-thioglucose—derived 
SGLT2 inhibitors, which have a sulfur atom in place of the oxygen atom in the glu-
cose ring [70]. It is known that 5′-thio-N-acetyllactosamine is 200 times more resist-
ant to digestion by β-galactosidase [71], and methyl α-5′-thiomaltoside is not hydro-
lyzed at all by glucoamylase [72]. In previous articles [73, 74], it was also described 
that O-aryl 5-thio-β-glucoside is a SGLT inhibitor. Kakinuma et  al. developed a 
synthetic strategy for preparing C-phenyl 1-thio-d-glucitol derivatives 290, as it is 
outlined in Scheme 46 [70]. Compounds 288 were obtained by adding thiolactone 
287 to Grignard reagents prepared from compounds 286 and magnesium powder. 
The hydroxyl group of 288 was reduced β-stereoselectively to afford compounds 
289. Finally, the benzyl ether of compounds 289 was removed by catalytic hydro-
genation with palladium hydroxide under a hydrogen atmosphere or, alternatively, 
compounds 290 were obtained by removal of the benzyl group using Lewis acid 
conditions to prevent reduction of the chloride (Scheme  46). (1S)-1,5-Anhydro-1-
[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol 290  (R1=OMe, 
 R2=Me,  R3=OEt) exhibited potent SGLT2 inhibition activity  (IC50 = 2.26 nM) [70]. 
Since 2014, this 1-thio-d-glucitol 290 has been known as luseogliflozin, and it is an 
orally active SGLT2 inhibitor developed by Taisho Pharmaceutical for the treatment 
of patients with type 2 diabetes mellitus [75].
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An approach to controlling blood glucose levels in individuals with type 2 diabe-
tes is to target R-amylases and intestinal glucosidases using R-glucosidase inhibitors 
acarbose and miglitol. One of the intestinal glucosidases targeted is the N-terminal 
catalytic domain of maltase-glucoamylase (ntMGAM), one of the four intestinal 
glycoside hydrolase 31 enzyme activities responsible for the hydrolysis of terminal 
starch products into glucose [76]. In 2010, Sim and coworkers presented the X-ray 
crystallographic studies of ntMGAM in complex with a new class of R-glucosidase 
inhibitors derived from natural extracts of Salacia reticulata, a plant used tradition-
ally in Ayurvedic medicine for the treatment of type 2 diabetes [76]. In extracts, 
active compounds were: salacinol 291, kotalanol 292, and de-O-sulfonated kotalanol 
293 (Fig. 14). This study revealed that kotalanol 293 is the most potent ntMGAM 
inhibitor reported to date (Ki = 0.03 μM), some 2000-fold better than the compounds 
currently used in the clinic, and highlights the potential of the salacinol class of 
inhibitors as future drug candidates [76].
In 2011, Wang et al. synthesized triazolyl phenylalanine and tyrosine-aryl C-gly-
coside hybrids via microwave-assisted Cu(I)-catalyzed azide-alkyne 1,3-dipolar 
cycloaddition [77]. Successive enzymatic assay identified the synthesized glycocon-
jugates as novel PTP1B inhibitors with low micromole-ranged inhibitory activity 
and at least several-fold selectivity over other homologous PTPs tested. As shown in 
Scheme 47, the azido phenylalaninyl or tyrosinyl derivatives 297 were synthesized 
according to the literature [78]. For the synthesis of the O-propynyl C-glycoside 
296, the known C-glucosyl 1,4-dimethoxybenzene 294 was first regioselectively 
silylated on its 6-position with TBDMSCl followed by full O-benzylation with NaH 
and BnBr. Then, the TBS group was desilylated with AcCl to give the free 6-OH, 
which was propargylated in the presence of NaH and propargyl bromide. Huisgen 
[3 + 2] cycloaddition between the azides 297 and the sugar alkyne 296 was catalyzed 
by sodium ascorbate and  CuSO4·5H2O yielding the click adducts 298 (Scheme 47). 
The saponification with LiOH led to the carboxylic acids 299. The following 
hydrogenolysis gave the fully deprotected amino acid-sugar hybrid 300. Benzyl 
groups on glucosyl moiety of compounds were found crucial for PTP1B inhibition. 
The biological assay identified the glycoconjugates that contain the carboxylic acid 
and benzyl moieties as more active PTP1B inhibitors compared to their ester and 
debenzylated counterparts [77].
In 2011, Kim et  al. designed and synthesized novel macrocyclic C-aryl gluco-
side SGLT2 inhibitors [79]. Two different synthetic routes of macrocyclization were 
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OH
HO
HO OH
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Fig. 14  Structures of R-glucosidase inhibitors from Salacia reticulata: salacinol 291, kotalanol 292, and 
de-O-sulfonated kotalanol 293 [76]
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adopted. Alkylation of alcohol 301 with (5-bromopentyloxy)(tert-butyl)-diphenyl-
silane 302 in the presence of sodium hydride in DMF produced 303 (Scheme 48). 
Desilylation of 303 with TBAF gave alcohol 304. Removal of the allyl group was 
carried out using  NaBH4 in the presence of tetrakis(triphenylphosphine) palla-
dium(0) to give phenol 305 in quantitative yield. The primary alcohol of 305 was 
transformed into the corresponding iodide 306 by action of iodine, triphenylphos-
phine, and imidazole in benzene. The iodide 306 underwent macrocyclization to 307 
under conditions of potassium carbonate and 18-crown-6 in DMF. Removal of the 
benzyl groups on the carbohydrate moiety proceeded with either  BCl3 in methyl-
ene chloride or hydrogenolysis on Pd/C in MeOH and THF to produce the target 
compound 308 (Scheme 48). Among the compounds tested, [1, 7] dioxacyclopenta-
decine macrocycles 308 possessing ethoxyphenyl at the distal ring showed the best 
in vitro inhibitory activity  (IC50 = 0.778 nM) against human hSGLT2 [79].
In 2012, Ohtake et  al. discovered a novel class of inhibitors, which have an 
O-spiroketal C-arylglucoside scaffold [80]. Compound 312  (R1=Et)—tofogliflozin 
(Scheme 49) is a selective SGLT2 inhibitor that is one of the inhibitors for the treat-
ment of type 2 diabetes. Ohtake et  al. worked on synthesis of tofogliflozin using 
the computational modeling and comparing other pharmacophore models that were 
derived from earlier inhibitors. O-Spiroketal C-arylglucosides 312 were prepared 
from 309 through two pathways, as outlined in Scheme 49. Compounds 311 were 
synthesized from the aldehyde 310, which could be obtained by oxidation of 309, 
followed by addition of Grignard reagents or lithiated benzenes and reduction. Com-
pounds 314 were prepared utilizing the Suzuki coupling reactions. After debenzyla-
tion of 309 using boron trichloride, benzyl alcohol moiety was selectively chlorin-
ated by treatment of chlorotrimethylsilane with dimethyl sulfoxide. Four hydroxyl 
groups of the resulting benzyl chloride were acetylated to afford 313. Suzuki cou-
pling reactions of 313 with the corresponding 4-substituted phenylboronic acids 
gave 314. Deprotections (debenzylation for 311 or deacetylation for 314) afforded 
the test compounds 312. Two products 312 (R=Et or iPr) were submitted to clinical 
trials. Both products showed a similar degree of increase in renal glucose excretion 
after oral dosing [80]. However, the next clinical trials turned out the 312 (R=Et) is 
much better, because it had more desirable profiles in oral bioavailability and renal 
excretion than 314 (R=iPr).
The discovery of structurally distinct SGLT2 inhibitors has been mainly focused 
on the modification of the aglycones, while modification to the glucose residue is 
less known. Therefore, in 2016 Yan and coworkers decided to examine a series of 
C-aryl glucosides containing dioxa-bicycle for inhibition activity against hSGLT2 
[81]. Ertugliflozin [82], bearing a unique dioxa-bicycle in place of the glucose resi-
due of dapagliflozin, is distinct from other inhibitors and shows even better SGLT2 
inhibitory activity, which is currently under phase III clinical trial. The synthesis of 
dioxa-bicycle C-aryl glucoside 327 is outlined in Scheme 50. Allylation of 315 in 
the presence of boron trifluoride etherate formed compound 316, which was con-
verted to ether 318. Conversion of the allyl intermediate 318 to aldehyde 320 using 
a Pd-catalyzed double-bond migration and next reaction with  K2Os2O4 and sodium 
periodate was made. Aldehyde 320 was then reduced to the alcohol 321, which 
was then protected as the methoxymethyl ether 322. Deprotection of TBSO ether 
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gave alcohol 323, and the primary hydroxyl group of 323 was subjected to iodina-
tion using  Ph3P, imidazole and iodine to give 324, which upon elimination using 
DBU in toluene furnished 325. Sharpless dihydroxylation and acid-promoted one-
pot MOM removal followed by stereoselective intramolecular trapping of the puta-
tive oxonium ion intermediate gave compound 326. Hydrogenolysis of the benzyl-
protecting groups yielded target compound 327 (Scheme 50). The target compound 
327 was subsequently subjected to biological evaluation as novel C-aryl glucoside 
SGLT2 inhibitor. Compound 327 showed good inhibitory activity against hSGLT2 
 IC50 = 714 nM [81].
According to our group interest of synthesis of C-glycosyl derivatives we also 
occupied in the synthesis of some derivatives. In 2013, we developed a conveni-
ent and efficient procedure for the preparation of fused uracils - pyrano[2,3-d]
pyrimidines with sugar moiety [83]. The reaction sequence was: Knoevenagel con-
densation of unprotected sugars 328 and 1,3-dimethylbarbituric acid 329 in water, 
acetylation of C-glycosides 330 and hetero-Diels–Alder reaction (Scheme  51). 
O-Acetylated 1,3-dimethyl-2,4,6-trioxo-pyrimidin-5-ylidene derivatives 331 were 
used as new heterodienes in the synthesis of pyrano[2,3-d]pyrimidines 333 and 
334 containing a sugar moiety. Solvent-free hetero-Diels–Alder cycloadditions of 
O-acetylated pyrimidin-5-ylidene alditols 331 with enol ethers 332 were investigated 
at room temperature. New, enantiomerically pure cis and trans diastereoisomers of 
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pyrano[2,3-d]pyrimidines 333 with alditol moiety were obtained. The same pyrimi-
din-5-ylidene alditols 331 underwent conjugate Michael addition-cyclizations with 
malononitrile 335 at room temperature to afford optically active uracils 336—
diastereoisomers of pyrano[2,3-d]pyrimidine-6-carbonitriles with a sugar moiety 
(Scheme 52) [83]. None of the C-glycosyl derivatives of pyrano[2,3-d]pyrimidines 
presented in Schemes  51 and 52 have been evaluated for their pharmacological 
activity as inhibitors in treatment of type 2 diabetes mellitus.
Our group also described a convenient and efficient method for the synthesis of 
chromeno[2,3-d]pyrimidine-2,4-diones containing different sugar moieties [84]. 
Dimedone enamines were used as dienophiles in hetero-Diels–Alder reactions. 
The cycloaddition reactions of O-acetylated 1,3-dimethyl-2,4,6-trioxo-pyrimidin-
5-ylidene alditols 337, representing a 1-oxa-1,3-butadiene system, with dimedone 
enamines 338 afforded only one enantiomerically pure cis diastereoisomer of 
330
N
NO
O
O
Na
O
OH
HO
OH328
O
R2
R5
R6 R1
R4
R3
R7
OH
O
OH
OH
HO
OH
328 L-(-)-Xylose, R1=R4=R5=OH, R2=R3=R6=R7=H
L-(+)-Arabinose, R1=R4=R6=R7=H, R2=R3=R5=OH
D-(+)-Glucose, R1=R4=R5=H, R2=R3=R6=OH, R7=CH2OH
D-(+)-Galactose, R1=R4=R6=H, R2=R3=R5=OH, R7=CH2OH
D-(-)-Ribose
N
NO
O
O
Na
O
R2
R5
R6 R1
R4
R3
R7
N
NO
O
O
329
5R
minorcis 334
+
7S
7R
minor 17 %major 54-73 %
332
+
OR10
331 L-Xylo, R1=R4=R5=R8=OAc, R2=R3=R6=R7=R9=H
L-Arabino, R1=R4=R6=R7=R9=H, R2=R3=R5=R8=OAc
D-Gluco, R1=R4=R5=R8=H, R2=R3=R6=R9=OAc, R7=CH2OAc
D-Galacto, R1=R4=R6=R8=H, R2=R3=R5=R9=OAc, R7=CH2OAc
D-Ribo, R1=R3=R5=R7=R9=H, R2=R4=R6=R8=OAc
332 R10=Et, isoBu
331
N
N OO
R2 R1
R4 R3
R6 R5
R8R9
R7
O
330 N
N OO
R2 R1
R4 R3
R6 R5
O
R9 R8
OR10
R7
H
H
trans 333cis 333
N
N OO
R2 R1
R4 R3
R6 R5
O
R9 R8
OR10
R7
H
H
+
5R
5S
7S
N
N OO
R2 R1
R4 R3
R6 R5
O
R9 R8
OR10
R7
H
H
5S
7R
N
N OO
R2 R1
R4 R3
R6 R5
O
R9 R8
OR10
R7
H
H
H2O, 80oC
Na2CO3
75-93 %
75-93 %
Ac2O, ZnCl2
r.t.
stirring
majortrans 334 65-72 %
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chromeno[2,3-d]pyrimidine-2,4-diones 339 in each reaction (Scheme 53). Analysis 
of NMR spectra allowed the determination that prepared fused uracils containing 
amino and enol functional groups exist as a mixture of the neutral form (NF) and 
zwitterions—dipolar ions (DI). By this simple hetero-Diels–Alder reaction, we can 
introduce into fused uracil systems such important for biological interaction groups 
as: different sugar moieties, enol moiety, and different amino groups. The prepared 
fused uracils contain both amine and enol functional groups, so share amphiprotic 
properties, and they are zwitterions in solid state [84]. None of the C-glycosyl deriv-
atives of chromeno[2,3-d]pyrimidines 339 have been examined as inhibitors in the 
treatment of type 2 diabetes.
Figure  15 presents inhibitory properties of the best inhibitors from the other 
C-glycosyl derivatives described in Sect. 4.3. The variety of active inhibitor struc-
tures is in this case greater than in the above-mentioned groups of glycosides. For 
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example, aryl butenoyl C-glycosides 277 can cause a significant decline in the 
hyperglycemia of the diabetic rats post sucrose-load. 5-Thioglucose—derived inhib-
itor 290, which has a sulfur atom in place of the oxygen atom in the glucose ring, 
is known as luseogliflozin and it is an orally active SGLT2 inhibitor for the treat-
ment of patients with type 2 diabetes mellitus. The activity of inhibitors may also 
be influenced by multivalency. On the basis of tests of trivalent inhibitors activity 
(for example compound 285), it was found that valency of the molecules influences 
slightly the inhibition of the enzyme, whereas the presence of a spacer arm between 
the core and the pharmacophore moieties does not. Multivalent inhibitors were 
Multivalent inhibitors were
always superior to their
monovalent counterparts.
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always superior to their monovalent counterparts. In turn, the natural C-glycoside 
kotalanol 293, which structures comprise a 1,4-anhydro-4-thio-d-arabinitol core and 
polyhydroxylated acyclic chain, is the most potent ntMGAM inhibitor reported to 
date (Ki = 0.03 μM) and highlights the potential of the salacinol class of inhibitors 
as future drug candidates. Active inhibitors can also be glycoconjugates, such as 
triazolyl phenylalanine and tyrosine-aryl C-glycoside hybrids (compound 299). Bio-
logical assay identified the glycoconjugates 299 that contain the carboxylic acid and 
benzyl moieties as more active PTP1B inhibitors compared to their ester and deben-
zylated counterparts. Also, macrocyclic C-glycosides may be active inhibitors. For 
example, [1, 7] dioxacyclopentadecine macrocycle 308 possessing ethoxyphenyl at 
the distal ring showed the best in vitro inhibitory activity  (IC50 = 0.778 nM) against 
human hSGLT2. Compound 312—tofogliflozin represents a novel class of SGLT2 
inhibitors, which have an O-spiroketal C-arylglucoside scaffold. In turn, ertugliflo-
zin 327 contains a unique dioxa-bicycle in place of the glucose residue of dapagli-
flozin, and is distinct from other inhibitors, and shows even better SGLT2 inhibitory 
activity.
5  Directions of the Latest Research in 2018–2019
In order to show the latest research directions, papers from 2018 to 2019 are 
described in a separate Sect. 5. When searching for articles on subject this publica-
tion, it was noted that the number of articles describing the synthesis of new inhibi-
tors decreased, and at the same time the number of publications depicting the extrac-
tion of active natural O-glycosides from plant materials increased. This trend applies 
in particular to 2018 and 2019. Sect. 5 presents articles on the latest modifications 
of the C-glycosides structure aimed at increasing their effectiveness as inhibitors. 
Suitable modifications were made to previously tested C-glycosides, in the agly-
cone structure as well as in the sugar molecule structure. Next, the latest proposals 
concerning the structure of N-glycosides as antidiabetic agents were presented and 
finally the structures of active O-glycosides isolated from plants were presented.
In 2018, Kerru et al. published a review article about current antidiabetic agents 
and their molecular targets [85]. In this review, authors described the use of hetero-
cyclic scaffolds, which have been evaluated for their biological response as inhibi-
tors against their respective antidiabetic molecular targets over the 5-year period 
from 2012 to 2017. Investigation reveals a diverse target set which includes pro-
tein tyrosine phosphatase 1 B (PTP1B), dipeptidly peptidase-4 (DPP-4), free fatty 
acid receptors 1 (FFAR1), G protein-coupled receptors (GPCR), peroxisome pro-
liferator activated receptor-g (PPARg), sodium glucose co-transporter-2 (SGLT2), 
α-glucosidase, aldose reductase, glycogen phosphorylase (GP), fructose-1,6-bispho-
sphatase (FBPase), glucagon receptor (GCGr), and phosphoenolpyruvate carbox-
ykinase (PEPCK). The article presents the structures of various active heterocyclic 
compounds, of which glycoside derivatives constitute a small group.
Kun and coworkers examined 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-
triazoles, which have been revealed as an effective scaffold for the development of 
potent glycogen phosphorylase inhibitors [86]. The potency of these compounds 
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is very sensitive to the nature of the alkyl/aryl 5-substituent. Authors have chosen 
for synthesis nine predicted candidates after in silico screening of 2335 new ana-
logues. The compounds 349 were prepared in O-perbenzoylated forms by either 
ring transformation of 5-β-d-glucopyranosyl tetrazole 340 by N-benzyl-arenecar-
boximidoyl chlorides, ring closure of C-(β-d-glucopyranosyl)formamidrazone 
341 with aroyl chlorides, or that of N-(β-d-glucopyranosylcarbonyl)arenethio-
carboxamides 347 by hydrazine, followed by deprotections (Scheme  54). Five 
compounds had Ki’s < 10 μM (349 a–e) with potent low μM inhibitors (rmGPa, 
hlGPa) and three of these (349a–c) on the submicromolar range for rmGPa [86]. 
The 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-triazoles described by Kun et al. 
are predicted to have drug-like potential with only permeability flagged as a 
potential issue to efficacy.
In 2018, Kyriakis et al. studied the inhibitory effect of different groups, in size 
and hydrophobicity, at the para position of 3-(β-d-glucopyranosyl)-5-phenyl-1, 
2, 4-triazoles 350 in hlGP by kinetics and X-ray crystallography (Fig. 16) [87]. 
The most bioactive compound was the one with an amine substituent to show a Ki 
value of 0.43 μM. The best C-β-d glucopyranosyl triazole GP inhibitor reported 
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thus far is the compound which has a 2-napthyl group and displays a Ki value of 
0.172 μM for the liver enzyme. Structural studies have revealed the physicochem-
ical diversity of the β-pocket providing information for future rational inhibitor 
design studies. Comparison of the Ki values of the inhibitors studied and their 
structural mode of binding revealed that the addition of the para group led to 
significant increments in potency only when this group exploited hydrophilic or 
hydrophobic interactions within the β-pocket [87].
Szennyes et  al. performed a systematic study on the preparation of 2-C-(β-d-
glucopyranosyl)pyrimidines [88]. Pinner-type cyclization of O-perbenzylated 
C-(β-d-glucopyranosyl)formamidine 351 with β-ketoesters, dimethyl malonate, and 
β-diketone-derived α,β-unsaturated β-chloroketones followed by catalytic hydro-
genation resulted in various substituted 2-C-(β-d-glucopyranosyl)-pyrimidin-4(3H)-
ones 354 (Scheme 55), and 2-C-(β-d-glucopyranosyl)-4,6-disubstituted-pyrimidines, 
respectively, in moderate to good yields. These pyrimidine derivatives were also 
obtained by ring closure of the unprotected C-(β-d-glucopyranosyl)formamidine 
352 with the same 1,3-dielectrophiles (Scheme  55). A continuous one-pot three-
step procedure starting from O-peracylated d-glycopyranosyl cyanides was also 
elaborated to give pyrimidines with various sugar configurations in overall yields 
(25–94%). These synthetic routes represent the first expansible method to obtain the 
target compounds. The C-glycopyranosyl pyrimidines showed moderate inhibition 
against α-glucosidase and β-galactosidase enzymes, and no activity against glycogen 
phosphorylase [88].
Kuo et  al. identified a good-in-class SGLT1/SGLT2 dual inhibitor to improve 
blood glucose control in type 2 diabetes [89]. The synthesis of benzocyclobutane-
C-glycosides 362 is described in Scheme  56. Lithium-halogen exchange of com-
pound 355 with n-BuLi, followed by the aldol condensation with compound 356 
formed 357. Reduction of compound 357 with TFA/Et3SiH gave 358. Treatment of 
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358 with n-BuLi, followed by the condensation with lactone 359, resulted in the for-
mation of lactol 360. Removal of the 1-OH group with  BF3.Et2O/Et3SiH provided 
compound 361. Deprotection of the benzyl-protecting groups with  BCl3/penta-meth-
ylbenzene gave benzocyclobutane-C-glycosides 362. The biological experiments 
were carried out on mice, rats, dogs, and monkeys. The best inhibitor 362  (R1=H, 
 R2=Cl) displayed very high inhibitory potency at both SGLT1  (IC50 = 45 nM) and 
SGLT2  (IC50 = 1 nM). New compounds have high in vivo efficacies in different ani-
mal model species [89].
In 2019, Kuroda and co-authors reported a discovery of an SGLT1 inhibitor C-phe-
nyl d-glucitol derivative 378  (R1=OMe,  R2=H,  R3=N,N-dimethylethylenediamine) 
(Scheme 57 and 58), with a glucose-lowering effect at a dose of 0.3 mg/kg (p.o.) 
in Sprague–Dawley (SD) rats [90]. The authors’ aim was to obtain a derivative that 
excretes mostly in bile to avoid retention of the drug in kidneys. The way of achiev-
ing this was imparting greater lipophilicity into the molecule by balancing ClogP and 
topological polar surface area (TPSA) together with the absorbability. The inhibitor 
378 was obtained in a multi-step synthesis in which as staring materials were used: 
3-isopropylphenol 363, lactone 366, and the compounds 370 and 371 (Schemes 57 
and 58). Compound 378  (R1=OMe,  R2=H,  R3=N,N-dimethylethylenediamine) 
showed hSGLT1  IC50 = 29  nM, hSGLT2  IC50 = 20  nM, ClogP = 3.66, and 
TPSA = 161 Å2. The authors concluded that the compound 378 could potentially be 
useful as a therapeutic agent for patients with T2DM [90].
In the next two articles discussed in the review, attempts were made to syn-
thesize active inhibitors by modifying the sugar part of the C-glycoside. In 
2018, Yuan and coworkers published an article which concerned the synthesis 
of 27 aryl C-glycosides bearing a C=N/C–N linkage at the glucosyl C6 posi-
tion [91]. All of these compounds were tested for their inhibitory activity against 
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sodium-dependent glucose co-transporter 2 (SGLT2). Among all obtained oxime 
ether derivatives 385, oxime (R=H) showed the best in vitro inhibitory activity 
(hSGLT2  EC50 = 46 nM, hSGLT1  EC50 = 3576 nM) and moreover no significant 
cytotoxicity and low human ether-à-go–go-related gene (hERG) inhibition. The 
mentioned oxime ether derivatives 385 were prepared starting from 5-bromo-
2-chloro-benzoic acid 379 as outlined in Scheme 59. A mixture of α- and β-C-
glucosides 380 was obtained in accordance with the procedure described in [41]. 
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The next step included regioselective 6-O-silylation and per-O-acetylation of 
380 to synthesize the fully protected β-C-glucoside 381. Then a reaction with 
boron trifluoride etherate in  CH2Cl2 and oxidation with Dess–Martin periodinane 
were carried out to introduce the aldehyde at C6 position. At the end, a conden-
sation of aldehyde 383 with different hydroxylamines in pyridine, followed by 
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deacetylation under Zemplén conditions led to obtain the desired oxime ether 
derivatives 385 [91].
The next article from 2018 from Sadurní et  al. concerned the influence of 
molecular editing with fluorine at the C2 position of the pyranose ring of phlori-
zin analogues to concurrently direct β-selective glycosylation [92]. The authors pro-
posed the methodology of fluorine-directed glycosylation to synthesize the selec-
tive SGLT2 inhibitors for type 2 diabetes. The mentioned phlorizin analogues were 
remogliflozin etabonate and dapagliflozin. These compounds, 396 and 397, con-
taining fluorine at C2 position were prepared starting from triacetyl-d-glucal 386 
as outlined in Scheme 60. A derivative 387 was obtained by the method described 
in Ref. [93]. The two glycosyl donors 388 and 389, required to access both target 
Scheme 59  Synthetic pathway of oxime ether derivatives 385 [91]
Scheme 60  Synthesis of remogliflozin etabonate and dapagliflozin analogues 396 and 397 [92]
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scaffolds, were formed according to the procedures presented in Scheme  60. The 
next steps in the synthesis of remogliflozin etabonate analogue included: glycosyla-
tion, benzyl-deprotection, and selective creation of the primary carbamate. Finally, 
the remogliflozin etabonate surrogate 396 was obtained. In the case of dapagliflo-
zin surrogate 397, the next steps involved the activation of 391 by halogen-lithium 
exchange and addition to the donor lactone 389, reduction with triethylsilane and 
 BF3·OEt2, benzyl-deprotection. Based on the conducted biological tests, it was 
found that the fluorinated dapagliflozin analogue 397 better selectively inhibited 
human SGLT2 over SGLT1 than remogliflozin etabonate analogue 396 [92].
Kun et  al. extended the structure–activity relationships of β-d-glucopyranosyl 
azole type inhibitors and revealed the extreme sensitivity of such type of inhibitor 
towards the structure of the azole moiety [94]. Actually, these compounds are the 
best glucose analogue inhibitors of GP known to date. Their efficiency, among other 
factors, is due to the formation of an H-bridge between the heterocycle and the His-
377 main chain carbonyl group in the active site of the enzyme [94]. 1-Aryl-4-β-
d-gluco-pyranosyl-1,2,3-triazoles were prepared by copper-catalyzed azide-alkyne 
cycloadditions between O-perbenzylated or O-peracetylated-β-d-glucopyranosyl 
ethynes and aryl azides. 1-β-d-Gluco-pyranosyl-4-phenyl imidazole was obtained in 
a glycosylation of 4(5)-phenylimidazole with O-peracetylated α-d-glucopyranosyl 
bromide. C-β-d-Glucopyranosyl-N-substituted-tetrazoles were synthesized by 
alkylation/arylation of O-perbenzoylated 5-β-d-glucopyranosyl-tetrazole or from a 
2,6-anhydroheptose tosylhydrazone and arenediazonium salts. 5-Substituted tetra-
zoles were glycosylated by O-peracetylated α-d-glucopyranosyl bromide 398 to 
give N-β-d-glucopyranosyl-C-substituted-tetrazoles 399 and 401 (Scheme 61) [94]. 
Standard deprotections gave test compounds that were assayed against rabbit muscle 
glycogen phosphorylase b. Most of the compounds proved inactive; the best inhibi-
tor was 2-β-d-glucopyranosyl-5-phenyltetrazole 400  (R1=Ph)  (IC50 600 μM).
Scheme 62 presents N-glucosyl indole derivatives, which were designed and syn-
thesized by Chu et al. in 2019 as sodium-dependent glucose co-transporter 2 inhibi-
tors [95]. The aim of the research was to check how modifications in the sugar part 
of the N-glucosyl indoles will affect their inhibitory properties. The synthesis of 
compounds 408 and 410 started from N-glucosyl indole 404. 6-Aldehyde 406 was 
obtained by selective protection of the primary alcohol 404 with tert-butylchlo-
rodimethylsilane (TBDMSCl), followed by immediate peracetylation by addition 
of acetic anhydride. Prepared the fully protected N-glucoside underwent desilyla-
tion under acidic conditions yielded the free primary alcohol 405. Dess–Martin 
periodinane (DMP) oxidation gave the desired aldehyde 406. Condensation of 406 
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with hydroxylamines and hydrazides followed by deacetylation gave oxime ethers 
407 and N-acylhydrazones 409. Reduction products, hydroxylamine N-glucosyl 
indoles 408 and hydrazide N-glucosyl indoles 410, were also synthesized using 
sodium cyanoborohydride  (NaBH3CN) under acidic conditions. Authors studied 
inhibitory activities  (EC50) of all synthesized N-glucosyl indole derivatives 407, 
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408, 409, 410, which were determined by measuring the inhibition by uptake of 
 [14C]-labeled α-methyl-d-glucopyranoside into hamster ovary cells stably expressing 
human hSGLT2 or hSGLT1 [95]. The compounds 407 and 409 had similar potency 
 (EC50 = 212–286  nM) except 409 (R=OEt,  EC50 = 1162  nM) and 409 (R=O-tert-
Bu,  EC50 = 867 nM). Compound 409 (R = Ph,  EC50 = 258 nM) was the most potent 
inhibitor of SGLT2. The next step was the examination of hydroxylamine deriva-
tives 408 and hydrazides 410. The products 408 and 410 are better inhibitors than 
substrates 407 and 409. The hydroxylamine derivatives 408 have similar potency 
 (EC50 = 45–294  nM). Taking into account the group of hydrazides 410, the most 
activite for hSGLT2 was compoud 410 (R=Me,  EC50 = 33 nM). Other hydrazides 
410 had their power within range  (EC50 = 63–1761 nM). Compound 410 (R=Me) 
was advanced into selectivity, pharmacokinetic, and in  vivo glucosuria studies. 
Unfortunately, it was found that this hydrazide has poor pharmacokinetic properties 
and increases glucosuria in rats only at high doses [95].
A variety of medicinal plants and their active compounds have been used to treat 
diabetes and related chronic disorders since ancient times. Recently, there is a grow-
ing interest in developing natural antidiabetic drugs to manage diabetic complica-
tions, especially from plant sources. Thus, due to the return to nature, attention was 
again paid to the structure of natural O-glycosides with antidiabetic action.
In 2018, Rosas-Ramírez et  al. postulated that resin glycosides from the morn-
ing glory family (Convolvulaceae) may be a source of phytotherapeutic agents with 
antihyperglycemic properties for the prophylaxis and treatment of non-insulin-
dependent type 2 diabetes mellitus [96]. Twenty-seven individual resin glycosides 
were evaluated for their α-glucosidase inhibitory potential. Four of these compounds 
displayed an inhibitory activity comparable to acarbose. In Fig. 17, compound 411 
presents the structure of one of the four active glycosides isolated from the morning 
glory family. Based on molecular modeling studies performed by docking analysis, it 
was predicted that the active compounds and acarbose bind to the α-1,4-glucosidase 
enzyme catalytic site of MAL12 from the yeast Saccharomyces cerevisiae through 
stable hydrogen bonds primarily with the amino acid residues HIS279 and GLN322 
[96]. Docking studies with the human maltase-glucoamylase (MGAM) also identi-
fied binding modes for resin glycosides inside the catalytic site in the proximity of 
TYR1251. Resin glycosides could help to control postprandial glucose levels due to 
their inhibitory activity of α-glucosidases, which play a crucial role in the produc-
tion of glucose [96].
In 2018, Kim and coworkers isolated from the seeds of Lens culinaris Medikus 
(Fabaceae) three flavonol glycosides and tested them for their DPP-IV–inhibitory 
activity [97]. Figure 17 contains the structure of one of the three active glycosides 
(compound 412) isolated from the morning glory family. Dipeptidyl peptidase IV 
(DPP-IV) is a new target for the treatment of type 2 diabetes mellitus. DPP-IV inhib-
itors shorten the inactivation of glucagon-like peptide 1 (GLP-1), permitting the 
incretin to stimulate insulin release, thereby combating hyperglycemia. It was dem-
onstrated for the first time that three isolated flavonol glycosides inhibited DPP-IV 
activity in a concentration-dependent manner in vitro bioassay system [97]. Molecu-
lar docking experiments of these compounds within the binding pocket of DPP-IV 
were also conducted. All investigated compounds readily fit within the active sites 
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of DPP-IV, in low-energy conformations characterized by the flavone core structure 
having optimal electrostatic attractive interactions with the catalytic triad residues of 
DPP-IV.
The use of steviol glycosides as non-caloric sweeteners has proven to be benefi-
cial for patients with type 2 diabetes mellitus, obesity, and metabolic syndrome [98]. 
Figure 17 shows the structure of one of the natural antidiabetic O-glycosides 413 
isolated from Stevia leaves. Recent data also demonstrate that steviol and stevioside 
might act as glucocorticoid receptor (GR) agonists and thus correlate with adverse 
effects on metabolism. In 2018, Panagiotou et al. provided strong evidence that ste-
viol and steviol glycosides exert GR-mediated effects in cancer Jurkat cells [98].
In 2018, Pham and coworkers examined the chemical composition of 
Gynostemma longipes, an ethnomedicinal plant used to treat type 2 diabetes mel-
litus by local communities in Vietnam [99]. Ten new dammarane triterpenes, 
including two hexanordammarane glycosides and five other dammarane glyco-
sides, were isolated from a ethanolic extract of the whole G. longipes plant. The 
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Fig. 17  Structures of natural O-glycosides with antidiabetic action isolated from plant sources: 411 
(morning glory family) [96], 412 (seeds of Lens culinaris Medikus) [97], 413 (leaves of Stevia rebaudi-
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structures of the new compounds were elucidated using diverse spectroscopic 
methods. All of the isolates were evaluated for their stimulatory activities on 
glucose uptake. Compound 414 (Fig. 17) showed particularly potent stimulatory 
effects [99].
Deepa et al. presented in the review paper that extracts from various species of 
Ficus and isolated compounds significantly have enhanced insulin secretion and 
subsequently reduced blood glucose level [100]. O-Glycosides (for example com-
pound 415, Fig. 17) isolated from Ficus species exhibited remarkable antidiabetic 
properties.
In 2018, Kekuda et al. prepared a comprehensive review about traditional uses, 
chemistry and pharmacological activities of Leea indica (Burm. f.) Merr.(Vita-
ceae) [101]. The plant L. indica is traditionally used, inter alia, as a medicine for 
diabetes. Hypoglycemic activity of alcoholic and hydroalcoholic extracts of L. 
indica leaves using glucose tolerance test and alloxan-induced diabetes model in 
rats, was evaluated. The extract administration significantly reduced blood glu-
cose levels, indicating hypoglycemic activity of leaf extracts [101]. Figure  17 
shows the structure of one of the natural O-glycosides (mollic acid arabinoside 
416) that have been isolated from the plant L. indica.
In another paper from 2018, Hua and coworkers have proven that green tea 
may favorably modulate blood glucose homeostasis, and regular consumption of 
green tea can prevent the development of type 2 diabetes mellitus [102]. Authors 
described the inhibition of α-glucosidase and α-amylase by flavonoid glyco-
sides from Lu’an GuaPian tea. The kaempferol monoglycoside showed inhibi-
tory activity against α-glucosidase with  IC50 at 40.02 ± 4.61 μM, and kaempferol 
diglycoside (Fig.  17, O-glycoside 417) showed α-amylase inhibition with  IC50 
at 0.09 ± 0.02 μM [95]. Application of Lu’an GuaPian green tea as a functional 
food ingredient can regulate postprandial hyperglycemia through inhibition of 
α-glucosidase/α-amylase by the mono and diglycosides of kaempferol [102].
Nile et  al. described valorization of onion solid waste and their flavonols for 
assessment of cytotoxicity, enzyme inhibitory, and antioxidant activities [103]. 
Onion (Allium cepa L.) is rich in flavonols like quercetin and quercetin glyco-
sides. These glycosides have been extracted and tested against enzymes of clini-
cal importance in diabetes. The samples exhibited significant antidiabetic effects. 
Results indicated that OSW (onion solid waste) and flavonol glycosides are poten-
tial antidiabetic agents [103]. Figure 17 shows the structure of one of the natural 
O-glycosides (quercetin-3,4′-O-diglucoside QDG 418) that have been isolated 
from onion solid waste.
Jayachandran and coworkers have designed studies to accumulate the experi-
mental evidence in support of antidiabetic effects of isoquercetin 419 (Fig.  17) 
[104]. Supplementation with isoquercetin significantly normalized blood sugar 
levels, insulin, and regulated the mRNA expression of insulin signaling genes and 
carbohydrate-metabolizing enzyme genes. The results achieved with isoquercetin 
are similar to that of the standard drug glibenclamide [104]. The findings suggest 
isoquercetin could be a possible therapeutic agent for treating diabetes mellitus in 
the near future.
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6  Biological Action of the Glycosides Described in this Review 
and Patents of Marketed Drugs
At present, the normalization of glycemia in diabetes is a rather complicated 
and problematic issue of diabetology. Despite the growing knowledge of vari-
ous chemical and biochemical aspects of diabetes mellitus, the specific molecular 
mechanisms leading to T2DM are still unknown. Current pharmacological treat-
ments are symptomatic and aim at maintaining blood glucose levels close to the 
fasting normoglycemic range of 3.5–6 mM/l. A large number of oral antidiabetic 
drugs, which exert their effects through various mechanisms, aimed at eliminat-
ing three major metabolic disorders leading to hyperglycemia: dysfunction of 
β-cells, peripheral insulin resistance, excessive hepatic glucose production [7]. 
Promising direction for design of new drugs for the treatment of diabetes mellitus 
is the regulation of key carbohydrate metabolism enzymes: inhibition of glycogen 
phosphorylase (GP), sodium-dependent glucose transporters (SGLT), and protein 
tyrosine phosphatase (PTP).
Depending on the binding site of the enzyme molecule, GP inhibitors are 
divided into compounds that block the catalytic site and compounds that block 
the allosteric sites [105, 106]. The following groups of chemical compounds were 
studied as inhibitors of the catalytic site of GP: N-acyl-β-(d-glucopyranosylamine 
derivatives, N-β-d-glucopyranosyl ureas, 2-(d-glucopyranosyl)-5-methyl-1,3,4-
oxadiazole derivatives, 2-(d-glucopyranosyl)-benzimidazoles, 3-substituted 
5-β-d-glucopyranosyl-1,2,4-oxadiazoles, glucopyranosyliden-spiro-thiohydan-
toins. Efforts in identifying the best heterocyclic junction between the glucose 
and pharmacophore units were patented, taking into account 1,2,4-triazole and 
imidazole moieties [107].
Inhibitors of sodium-dependent glucose co-transporter 2 (SGLT2) are an 
attractive method of type 2 diabetes treatment because of their distinct mecha-
nism of action, in which blood glucose levels are reduced independently of insu-
lin secretion [108]. In healthy individuals, greater than 99% of the plasma glucose 
that is filtered in the kidney is reabsorbed, resulting in less than 1% of the total fil-
tered glucose being excreted in urine [41]. This reabsorption process is mediated 
by two sodium-dependent glucose cotransporters (SGLTs): SGLT1, a low-capac-
ity, high-affinity transporter and SGLT2, a high-capacity, low-affinity transporter 
that is expressed mainly in the kidney [41]. It is estimated that 90% of renal glu-
cose reabsorption is facilitated by SGLT2 residing on the surface of the epithelial 
cells lining the S1 segment of the proximal tubule; the remaining 10% is likely 
mediated by SGLT1 localized on the more distal S3 segment of the proximal 
tubule [41]. Several selective SGLT2 inhibitors have been developed by structural 
modification of phlorizin, the first known SGLT inhibitor. C-Linked β-glycosides 
(gliflozins) are at advanced stages of development because of their metabolic 
stability, high oral bioavailability, and plasma exposure. Of these, dapagliflozin, 
canagliflozin, ipragliflozin, empagliflozin, tofogliflozin, luseogliflozin, ertugli-
flozin, and sotagliflozin have been approved for the treatment of type 2 diabetes 
mellitus recently [108]. These compounds are now approved as marketed drugs 
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(Fig. 18). For example, inhibition of SGLT2 with Forxiga (dapagliflozin) reduces 
renal glucose reabsorption and thereby increases urinary glucose exretion [109]. 
From 2014, Forxiga is indicated by the FDA as an adjunct to diet and exercise to 
improve glycemic control in adults with type 2 diabetes and is not recommended 
for patients with type 1 diabetes mellitus.
Of particular importance to the downregulation of insulin signaling is pro-
tein tyrosine phosphatase 1B (PTP1B), which dephosphorylates the receptor (IR) 
on the surface of a cell [110]. Inhibition of PTP1B may represent a practical strat-
egy for the treatment of type 2 diabetes [111]. Various strategies have been devel-
oped to design and synthesize potent and selective PTP1B inhibitors. The principal 
approach is based on mimicking the phosphotyrosine moiety. Many PTP inhibitors 
contain a quinone functionality. Series of C-glucosyl 1,4-benzo- and 1,4-naphtho-
quinones were found as better PTP1B inhibitors than their analogues displaying 
1,4-dimethoxybenzene or -naphthalene residues [40]. Modifications of molecules at 
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the primary 6-position were made by transformation to either carboxylic, azido, or 
benzamido groups, or elongation by azide-alkyne click chemistry to triazole ring 
formation [112].
7  Conclusions
In this review, we disclosed studies on the preparation of glycosides that can be 
applied as inhibitors of glycogen phosphorylase, sodium glucose cotransporter 2, 
protein tyrosine phosphatase 1B and other more specific enzymes. The natural prod-
uct phlorizin was identified as the first type 2 diabetes mellitus inhibitor. Because 
O-glycosides are usually hydrolytically unstable, many carbohydrate analogues such 
as N-glycosides and C-glycosides have been synthesized and used as enzyme inhibi-
tors. In comparison to O-glycosides, the C-glycosides are structurally more stable 
against acidic and enzymatic cleavage due to the existence of their C–C glycosidic 
bond. Among glycomimetics, C-glycosyl compounds have attracted much attention. 
By use of structure–activity relationships, several new glycosides have been devel-
oped as inhibitors and studied in clinical trials. Some of the described glycoside-
based molecules, for example dapagliflozin, canagliflozin, ipragliflozin, empagliflo-
zin, tofogliflozin, luseogliflozin, ertugliflozin, and sotagliflozin, have been approved 
as marketed drugs.
Figure  19 shows the best GPb inhibitors described in this article, which were 
selected from Figs. 7, 9, 10, 11, 13, and 15 presenting activity of inhibitors having 
a specific O, N, or C-glycoside structure and from Sect. 5 describing directions of 
the latest research from 2018 to 2019. Below each compound there is information 
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about what type of glycoside it represents. The compounds were ranked in order 
from the inhibitor with the highest activity (the lowest Ki) to the inhibitor with the 
lowest activity (the highest Ki). Where the Ki values were not reported in the publi-
cation, the inhibitory properties were compared based on the  IC50 values. Seven of 
the eight inhibitors shown in Fig. 19 are derivatives of d-glucose. Changes in the 
sugar configuration as well as removal or replacement of substituents of the glucose 
moiety proved detrimental for the inhibition. The crucial role of the aglycon in the 
efficiency of the inhibitors is also presented in this article. Based on the analysis of 
the structure of compounds that are the best GPb inhibitors, it can be concluded that 
a high activity is ensured by the presence of the 2-naphthol group. Four of the eight 
compounds shown in Fig. 19 have a 2-naphthol group. Analysis of the structures of 
the best GPb inhibitors (Fig. 19) leads to the conclusion that the highest activity is 
possessed by inhibitors containing, as aglycones, heterocyclic rings with nitrogen 
atoms.
In turn, Fig. 20 presents the best SGLT2 inhibitors. They were selected from 
Figs. 7, 9, 10, 11, 13, and 15 as representatives of glycosides with the structure 
described in the given Sects and from Sect. 5 describing directions of the latest 
research from 2018 to 2019. The compounds were arranged in order from the best 
inhibitor (the lowest  IC50) to the inhibitor with lower activity (the highest  IC50). 
The activity of inhibitors for which no  IC50 values were reported in the publica-
tion was evaluated by comparing the  EC50 values. Analysis of the structure of 
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the best SGLT2 inhibitors allows the conclusion that not only glucose but also 
its derivatives or xylose provide inhibitory activity. Looking at the structure of 
active SGLT2 inhibitors from Fig. 20, it can also be seen that each of them has 
one or two phenyl groups in its structure. Considering the structure of the agly-
cone, one cannot distinguish a specific heteroaromatic system whose structure 
would be repeated in the structure of the inhibitors considered. However, it can 
be seen that in two cases there is a thiophene ring and in the other two an indole 
system. Eight of the ten SGLT2 inhibitors shown in Fig.  20 have a chlorine or 
fluorine atom in their structure.
The conclusions drawn from the analysis of the structure of the best inhibitors 
should be taken into account when designing antidiabetic drugs. We sincerely hope 
that this article will stimulate further research in glycoside derivatives synthesis and 
will encourage scientists to design novel inhibitors in the treatment of type 2 diabe-
tes mellitus.
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